Document:

EX-10.3

 Exhibit 10.3 

EXECUTION COPY 
 ***Text Omitted and Filed
Separately with the Securities and Exchange Commission 
 Confidential Treatment Requested Under 

17 C.F.R. Sections 200.80(b)(4) and 240.24b-2 

Ex-US Commercialization Agreement 
 This
Agreement is entered into with effect as of the Effective Date (as defined below) 
 by and between 

F. Hoffmann-La Roche Ltd 
 with an office and place of
business at Grenzacherstrasse 124, 4070 Basel, Switzerland (“Roche”) 
 on the one hand 

and 
 Foundation Medicine, Inc. 

with an office and place of business at 150 Second Street, Cambridge, Massachusetts 02141 (“FMI”) 

on the other hand. 

  

 Table of Contents 

 

							
	 1.           
		 Definitions
		 	1	  
			 1.1        [...***...] Region
		 	1	  
			 1.2        Affiliate
		 	2	  
			 1.3        Agreement
		 	2	  
			 1.4        Agreement Term
		 	2	  
			 1.5        Allocable Overhead Expenses
		 	2	  
			 1.6        Applicable Law
		 	2	  
			 1.7        Business Day
		 	2	  
			 1.8        Calendar Quarter
		 	3	  
			 1.9        Calendar Year
		 	3	  
			 1.10      Commercially Launch(ed)
		 	3	  
			 1.11      Commercially Reasonable Efforts
		 	3	  
			 1.12      Confidential Information
		 	3	  
			 1.13      Control
		 	3	  
			 1.14      Cost of Services
		 	4	  
			 1.15      Cover
		 	4	  
			 1.16      Effective Date
		 	4	  
			 1.17      EMA
		 	4	  
			 1.18      EU
		 	4	  
			 1.19      Existing Third Party Rights
		 	5	  
			 1.20      FMI Know-How
		 	5	  
			 1.21      FMI Patent Rights
		 	5	  
			 1.22      FMI Territory
		 	5	  
			 1.23      FMI Trademarks
		 	5	  
			 1.24      FTE
		 	5	  
			 1.25      Gross Margin
		 	5	  
			 1.26      HSR
		 	5	  
			 1.27      IFRS
		 	5	  
			 1.28      Insolvency Event
		 	5	  
			 1.29      JMC
		 	6	  
			 1.30      JOC
		 	6	  
			 1.31      Know-How
		 	6	  
			 1.32      Net Sales
		 	6	  
			 1.33      Non-Europe Region
		 	6	  
			 1.34      [...***...] Region
		 	6	  
			 1.35      Party
		 	6	  
			 1.36      Patent Rights
		 	6	  
			 1.37      Post Approval Plan
		 	6	  
			 1.38      Product
		 	6	  
			 1.39      Quality Standards
		 	7	  
			 1.40      Region
		 	7	  
			 1.41      Regulatory Approval
		 	7	  
			 1.42      Regulatory Authority
		 	7	  
			 1.43      Roche Group
		 	7	  
			 1.44      Sales
		 	7	  
			 1.45      Sublicensee
		 	7	  
			 1.46      Tactical Plan
		 	7	  
			 1.47      Territory
		 	8	  

  
 ***Confidential Treatment
Requested*** 
 - ii - 

							
			 1.48      Third Party
		 	8	  
			 1.49      US
		 	8	  
			 1.50      US$
		 	8	  
			 1.51      Additional Definitions
		 	8	  
	 2.           
		 Licensesand Exclusivity
		 	9	  
			 2.1        Licenses
		 	9	  
			 2.2        Exclusive Right to Commercialize Products
		 	10	  
	 3.           
		 Right    to Include Future Products
		 	11	  
	 4.           
		 Governance
		 	11	  
			 4.1        Joint Management Committee
		 	11	  
			 4.2        Joint Operational Committee
		 	11	  
			 4.3        Members
		 	12	  
			 4.4        Responsibilities of the JOC
		 	12	  
			 4.5        Meetings
		 	13	  
			 4.6        Minutes
		 	13	  
			 4.7        Decisions
		 	13	  
			 4.8        Information Exchange
		 	14	  
			 4.9        Joint Operational Teams
		 	14	  
			 4.10      Alliance Director
		 	14	  
			 4.11      Limitations of Authority
		 	14	  
			 4.12      Expenses
		 	14	  
			 4.13      Lifetime
		 	14	  
	 5.           
		 Supply 
		 	14	  
	 6.           
		 Regulatory
		 	15	  
			 6.1        Responsibility
		 	15	  
			 6.2        Clinical Trials
		 	15	  
			 6.3        Reporting Adverse Events
		 	16	  
			 6.4        Reimbursement
		 	16	  
	 7.           
		 Commercialization
		 	16	  
			 7.1        Business Planning Period
		 	16	  
			 7.2        Reduction in Scope of Territory
		 	16	  
			 7.3        Sales
		 	17	  
			 7.4        Territory, Initial Launch and Launch Delay Fee
		 	17	  
			 7.5        Responsibility
		 	17	  
			 7.6        Branding and Pricing
		 	20	  
			 7.7        Product Promotional Materials
		 	20	  
	 8.           
		 Payment
		 	21	  
			 8.1        General
		 	21	  
			 8.2        Costs of Services
		 	21	  
			 8.3        Royalty Payments and Sales Milestones
		 	22	  
			 8.4        Disclosure of Payments
		 	23	  
	 9.           
		 Accountingand Reporting
		 	23	  
			 9.1        Timing of Payments
		 	23	  
			 9.2        Late Payment
		 	23	  
			 9.3        Method of Payment
		 	23	  
			 9.4        Currency Conversion
		 	24	  
			 9.5        Reporting
		 	24	  
	 10.        
		 Taxes   
		 	24	  
	 11.        
		 Auditing
		 	24	  

  
 - iii - 

							
			 11.1      Right to Audit
		 	24	  
			 11.2      Audit Reports
		 	25	  
			 11.3      Over-or Underpayment
		 	25	  
			 11.4      Duration of Audit Rights
		 	25	  
	 12.        
		Intellectual Property		 	25	  
			 12.1      Ownership of Inventions
		 	25	  
			 12.2      Trademarks and Labeling
		 	25	  
			 12.3      Prosecution of Patent Rights
		 	26	  
			 12.4      Patent Coordination Team
		 	26	  
			 12.5      Infringement
		 	26	  
			 12.6      Defense
		 	26	  
			 12.7      Common Interest Disclosures
		 	27	  
	 13.        
		 Representationsand Warranties
		 	27	  
			 13.1      FMI Representations and Warranties
		 	27	  
			 13.2      Mutual Representations of the Parties
		 	28	  
	 14.        
		 Indemnification
		 	29	  
	 15.        
		 Liability
		 	29	  
			 15.1      Disclaimer
		 	29	  
	 16.        
		 ObligationNot to Disclose Confidential Information
		 	30	  
			 16.1      Non-Use and Non-Disclosure
		 	30	  
			 16.2      Permitted Disclosure
		 	30	  
			 16.3      Press Releases
		 	30	  
			 16.4      Publications
		 	30	  
			 16.5      Commercial Considerations
		 	31	  
	 17.        
		 Term    and Termination
		 	31	  
			 17.1      Commencement and Term
		 	31	  
			 17.2      Termination
		 	31	  
			 17.3      Consequences of Termination and Expiration
		 	32	  
			 17.4      Survival
		 	36	  
	 18.        
		 Bankruptcy
		 	36	  
	 19.        
		 Miscellaneous
		 	36	  
			 19.1      Governing Law
		 	36	  
			 19.2      Disputes
		 	36	  
			 19.3      Arbitration
		 	37	  
			 19.4      Assignment
		 	38	  
			 19.5      Compliance with Applicable Law
		 	38	  
			 19.6      Debarment
		 	38	  
			 19.7      Independent Contractor
		 	39	  
			 19.8      Unenforceable Provisions and Severability
		 	39	  
			 19.9      Waiver
		 	39	  
			 19.10    Appendices
		 	39	  
			 19.11    Entire Understanding
		 	39	  
			 19.12    Amendments
		 	40	  
			 19.13    Invoices
		 	40	  
			 19.14    Notice
		 	40	  
			 19.15    Subcontractors
		 	40	  
			 19.16    Force Majeure
		 	41	  

  
 - iv - 

 Ex-US Commercialization Agreement 

WHEREAS, FMI has certain products that it currently commercializes, FoundationOne® and FoundationOne® Heme, and would like to commercialize, either by itself or through a collaborator, additional products in the future; and 

WHEREAS, Roche has expertise in the commercialization of pharmaceutical and diagnostic products; and 

WHEREAS, Roche and FMI want to collaborate on the commercialization of certain FMI products outside of the US; and 

WHEREAS, Roche and FMI are concurrently herewith entering into that certain transaction agreement dated as of the date hereof (as it may be amended from time
to time, the “Transaction Agreement”) which provides, among other things, for Roche to acquire a majority ownership of FMI upon the terms and subject to the conditions set forth in the Transaction Agreement, and a related investor
rights agreement, “Investor Rights Agreement”); and 
 WHEREAS, in connection therewith, and as an inducement to Roche’s and
FMI’s willingness to enter into the Transaction Agreement and to consummate the transactions contemplated thereby, the Parties hereto agree that , Roche will work with FMI in the United States to educate relevant persons on next generation
sequencing and/or comprehensive genomic profiling technology pursuant to the US educaton collaboration agreement dated as of the date hereof (as it may be amended from time-to-time, the “US Education Collaboration Agreement”), Roche
will collaborate with FMI on the development of genomic testing platforms (“Collaboration Agreement”), and Roche and FMI wll evaluate a collaboration on certain diagnostics, including certain decentralized IVD diagnostics generated
by FMI pursuant to the IVD collaboration termsheet dated as of the date hereof (as it may be amended from time-to time, the “IVD Collaboration”, together with the US Education Collaboration Agreement and the IVD Collaboration, the
“Related Agreements” ); and 
 WHEREAS, FMI and Roche intend that assays and other products generated under the Collaboration Agreement
will be commercialized in accordance with this Agreement. 
 NOW, THEREFORE, in consideration of the mutual covenants and promises contained in this
Agreement and other good and valuable consideration, the receipt and sufficiency of which are hereby acknowledged, the Parties hereto, intending to be legally bound, do hereby agree as follows: 

 

	1.	Definitions 

 As used in this Agreement, the following terms, whether used in the singular or plural,
shall have the following meanings: 
  

	 	1.1	[...***...] Region 

 The term “[...***...] Region” shall mean [...***...].

  
 ***Confidential Treatment
Requested*** 

	 	1.2	Affiliate 

 The term “Affiliate” shall mean any individual, corporation, association or other
business entity that directly or indirectly controls, is controlled by, or is under common control with the Party in question. As used in this definition of “Affiliate,” the term “control” shall mean the direct or indirect
ownership of more than fifty percent (>50%) of the stock having the right to vote for directors thereof or the ability to otherwise control the management of the corporation or other business entity whether through the ownership of voting
securities, by contract, resolution, regulation or otherwise. Anything to the contrary in this paragraph notwithstanding, Chugai Pharmaceutical Co., Ltd, a Japanese corporation (“Chugai”), shall not be deemed an Affiliate of Roche unless
Roche provides written notice to FMI of its desire to include Chugai as an Affiliate of Roche. Moreover, FMI and its Affiliates existing as of the Effective Date shall not be deemed Affiliates of Roche and its Affiliates existing as of the Effective
Date, and Roche and its Affiliates existing as of the Effective Date shall not be deemed Affiliates of FMI and its Affiliates existing as of the Effective Date. Affiliates coming into existence after the Effective Date shall be classified by the
Parties as either Roche Affiliates or FMI Affiliates for the purposes of this Agreement. 
  

	 	1.3	Agreement 

 The term “Agreement” shall mean this document including any and all appendices and
amendments to it as may be added and/or amended from time to time in accordance with the provisions of this Agreement. 
  

	 	1.4	Agreement Term 

 The term “Agreement Term” shall mean the period of time commencing on the
Effective Date and, unless this Agreement is terminated sooner as provided in Article 17, expiring five (5) years from the Effective Date (“Initial Term”) unless extended by Roche in writing at least [...***...] prior to
the expiration of the Initial Term (or any Renewal Term) (i) in its entirety, (ii) on a country-by-country, Region by Region and/or Product-by-Product basis, or (iii) by mutual agreement of the Parties, in each case for additional two (2) year
periods (each a “Renewal Term”) during any period of time in which the Aggregate Ownership Percentage (as defined in the Investor Rights Agreement) of Roche and its Affiliates is at least 50.1% (it being understood that this
requirement is subject to Section 4.04 of the Investor Rights Agreement). 
  

	 	1.5	Allocable Overhead Expenses 

 The term “Allocable Overhead Expenses” shall mean costs incurred
by a Party for its account which are attributable to the Party’s supervisory, services, occupancy costs, corporate bonus (to the extent not charged directly to department), and its payroll, information systems, human relations or
purchasing functions and which are allocated to company departments based on space occupied or headcount or other activity-based method. Allocable Overhead Expenses shall not include any costs attributable to general corporate activities including
executive management, investor relations, business development, legal affairs and finance. 
  

	 	1.6	Applicable Law 

 The term “Applicable Law” shall mean any law, statute, ordinance, code, rule
or regulation that has been enacted by a government authority (including without limitation, any Regulatory Authority) and is in force as of the Effective Date or comes into force during the Agreement Term, in each case to the extent that the same
is applicable to the performance by the Parties of their respective obligations under this Agreement. 
  

	 	1.7	Business Day 

 The term “Business Day” shall mean 9:00 a.m. to 5:00 p.m. local time on a day
other than a Saturday, Sunday or bank or other public or federal holiday in Switzerland, New Jersey or Massachusetts. 

  
 ***Confidential Treatment
Requested*** 
 - 2 - 

	 	1.8	Calendar Quarter 

 The term “Calendar Quarter” shall mean each period of three
(3) consecutive calendar months, ending March 31, June 30, September 30, and December 31. 
  

	 	1.9	Calendar Year 

 The term “Calendar Year” shall mean the period of time beginning on
January 1 and ending December 31, except for the first year which shall begin on the Effective Date and end on December 31. 
  

	 	1.10	Commercially Launch(ed) 

 The term “Commercially Launch(ed)” shall mean a commercial launch of
a particular Product, which shall at a minimum require at least commercial scale sales, marketing and promotional activities using Commercially Reasonable Efforts. 
  

	 	1.11	Commercially Reasonable Efforts 

 The term “Commercially Reasonable Efforts” shall mean such
level of efforts required to carry out such obligation in a sustained manner consistent with the efforts that Roche or FMI, as applicable, devotes at the same stage of development or commercialization, as applicable, for its own products with
similar market potential, at a similar stage of their product life taking into account the existence of other competitive products in the market place or under development, the proprietary position of the product, the regulatory structure involved,
the anticipated profitability of the product and other relevant factors. It is understood that such product potential may change from time to time based upon changing scientific, business and marketing and return on investment considerations. 

 

	 	1.12	Confidential Information 

 The term “Confidential Information” shall mean any and all
information, data or know-how (including Know-How), whether technical or non-technical, oral or written, that is disclosed by one Party or its Affiliates (“Disclosing Party”) to the other Party or its Affiliates (“Receiving
Party”). Confidential Information shall not include any information, data or know-how that: 
  

	 	(i)	was generally available to the public at the time of disclosure, or becomes available to the public after disclosure by the Disclosing Party other than through fault (whether by action or inaction) of the Receiving
Party or its Affiliates, 

  

	 	(ii)	can be evidenced by written records to have been already known to the Receiving Party or its Affiliates prior to its receipt from the Disclosing Party, 

 

	 	(iii)	is obtained at any time lawfully from a Third Party under circumstances permitting its use or disclosure, 

  

	 	(iv)	is developed independently by the Receiving Party or its Affiliates as evidenced by written records other than through knowledge of Confidential Information, or 

 

	 	(vi)	is approved in writing by the Disclosing Party for release by the Receiving Party. 

 The terms of this
Agreement shall be considered Confidential Information of the Parties. 
  

	 	1.13	Control 

 The term “Control” shall mean (as an adjective or as a verb including conjugations
and variations such as “Controls” “Controlled” or “Controlling”) (a) with respect to Patent Rights and/or Know-How, the possession by a Party of the ability to grant a license or sublicense of such Patent

  
 - 3 - 

 
Rights and/or Know-How without violating the terms of any agreement or arrangement between such Party and any other party and (b) with respect to proprietary materials, the possession by a
Party of the ability to supply such proprietary materials to the other Party as provided herein without violating the terms of any agreement or arrangement between such Party and any other party. 

 

	 	1.14	Cost of Services 

 The term “Cost of Services” means, as applicable to a Product, FMI’s
costs incurred in connection with sample preparation, sequencing, data analysis, medical curation and report generation (collectively, “Service Activities” for such Product), equal to (a) [...***...] and (b)
[...***...]. The Cost of Services shall be calculated in accordance with GAAP, or IFRS, as applicable and as consistently applied by FMI in preparing its audited consolidated financial statements. FMI shall be solely responsible for all
capital costs incurred in connection with providing the Service Activities for Products for use in the Territory, including without limitation building out capacity for such Products, provided that depreciation for any equipment used to provide the
Service Activities will be included in the Cost of Services to the extent allocable to a Product in a manner consistent with FMI’s internal and external accounting principles as consistently applied. Except as provided for in Section 8.2,
Cost of Services will not include any transfer pricing mark-up. For clarity, any given deduction utilized in calculating Cost of Services (including the components thereof) shall be taken only once. 

 

	 	1.15	Cover 

 The term “Cover” shall mean (as an adjective or as a verb including conjugations and
variations such as “Covered,” “Coverage” or “Covering”) that the developing, making, using, offering for sale, promoting, selling, exporting or importing of a given compound, formulation or product would infringe a
valid claim in the absence of a license under the Patent Rights to which such valid claim pertains. The determination of whether a compound, formulation, process or product is covered by a particular valid claim shall be made on a country-by-country
basis. As used in the previous sentence, “valid claim” means, with respect to a particular country a claim in an issued and unexpired patent that has not lapsed or been disclaimed, revoked, held unenforceable, unpatentable or invalid by a
decision of a court or other governmental agency of competent jurisdiction, unappealable or unappealed within the time allowed for appeal and that has not been admitted to be invalid or unenforceable through re-examination, re-issue, disclaimer or
otherwise, or lost in an interference proceeding. 
  

	 	1.16	Effective Date 

 The term “Effective Date” shall mean the effective date of the Collaboration
Agreement. 
  

	 	1.17	EMA 

 The term “EMA” shall mean the European Medicines Agency or any successor agency with
responsibilities comparable to those of the European Medicines Agency. 
  

	 	1.18	EU 

 The term “EU” shall mean the European Union and all its then-current member countries.

  
 ***Confidential Treatment
Requested*** 
 - 4 - 

	 	1.19	Existing Third Party Rights 

 The term “Existing Third Party Rights” shall mean any Third Party
rights granted by FMI to such Third Party relating to the Products in the Territory under an agreement with FMI existing as of the Effective Date. The Existing Third Party Rights are listed in Appendix 1.19. 

 

	 	1.20	FMI Know-How 

 The term “FMI Know-How” shall mean the Know-How that FMI Controls at the
Effective Date and during the Agreement Term. 
  

	 	1.21	FMI Patent Rights 

 The term “FMI Patent Rights” shall mean the Patent Rights that FMI Controls
Covering a Product or its use. 
  

	 	1.22	FMI Territory 

 The term “FMI Territory” shall mean (i) the US, (ii) any countries
that have been excluded during or after the Business Planning Period, and (iii) any countries that have been removed from the Territory pursuant to the terms of this Agreement. 

 

	 	1.23	FMI Trademarks 

 The term “FMI Trademarks” shall mean all trademarks Controlled by FMI which
are necessary or useful for use in connection with the commercialization of Products. 
  

	 	1.24	FTE 

 The term “FTE” shall mean a full-time equivalent person-year, based upon a total of no
less than one thousand eight hundred (1,800) working hours per year, undertaken in connection with the conduct of research in the Research Program. In no circumstance can the work of any given person exceed one (1) FTE. 

 

	 	1.25	Gross Margin 

 The term “Gross Margin” shall mean Net Sales minus Cost of Services. 

 

	 	1.26	HSR 

 The term “HSR” shall mean the Hart-Scott-Rodino Antitrust Improvements Act. 

 

	 	1.27	IFRS 

 The term “IFRS” shall mean International Financial Reporting Standards. 

 

	 	1.28	Insolvency Event 

 The term “Insolvency Event” shall mean circumstances under which a Party
(i) has a receiver or similar officer appointed over all or a material part of its assets or undertaking; (ii) passes a resolution for winding-up (other than a winding-up for the purpose of, or in connection with, any solvent amalgamation
or reconstruction) or a court makes an order to that effect or a court makes an order for administration (or any equivalent order in any jurisdiction); (iii) enters into any composition or arrangement with its creditors (other than relating to
a solvent restructuring); (iv) ceases to carry on business; (v) is unable to pay its debts as they become due in the ordinary course of business. 

  
 - 5 - 

	 	1.29	JMC 

 The term “JMC” shall mean the joint management committee described in Article 6 of the
Collaboration Agreement. If the Collaboration Agreement terminates before this Agreement, then the provisions of the Collaboration Agreement to the necessary to interpret or implement this Agreement shall be incorporated by reference into this
Agreement. 
  

	 	1.30	JOC 

 The term “JOC” shall mean the joint operating committee as mentioned in the Collaboration
Agreement and the US Education Collaboration Agreement, and described in Section 4.2. 
  

	 	1.31	Know-How 

 The term “Know-How” shall mean data, knowledge and information, including chemical
manufacturing data, toxicological data, pharmacological data, preclinical data, assays, platforms, formulations, specifications, quality control testing data, that are necessary or useful for the discovery, manufacture, development or
commercialization of Products. 
  

	 	1.32	Net Sales 

 The term “Net Sales” shall mean, for a Product in a particular period, the amount
calculated by subtracting from the Sales of such Product for such period: (i) [...***...]. 
  

	 	1.33	Non-Europe Region 

 The “Non-Europe Region” shall mean all countries in the Territory excluding
the [...***...] Region and the [...***...] Region. 
  

	 	1.34	[...***...] Region 

 The term “[...***...] Region” shall mean [...***...].

  

	 	1.35	Party 

 The term “Party” shall mean FMI or Roche, as the case may be, and “Parties”
shall mean FMI and Roche collectively. 
  

	 	1.36	Patent Rights 

 The term “Patent Rights” shall mean all rights under any patent or patent
application, in any country of the Territory, including any patents issuing on such patent application, and further including any substitution, extension or supplementary protection certificate, reissue, reexamination, renewal, division,
continuation or continuation-in-part of any of the foregoing. 
  

	 	1.37	Post Approval Plan 

 The term “Post Approval Plan” shall mean the plan for regulatory
(including the strategy with respect to Regulatory Approvals and reimbursement approvals for Products) and clinical activities associated with a Product in the Territory. 
  

	 	1.38	Product 

 The term “Product” shall mean (i) FoundationOne® and FoundationOne®
Heme, and any updated and successor versions to FoundationOne® and FoundationOne® Heme, including any updated and successor versions with updated gene lists or that provide clinical outcome data (collectively, “Initial
Products”), (ii) any clinical diagnostic testing commercial products developed under the Immunotherapy Testing Platform Development Program (as defined in the 

  
 ***Confidential Treatment
Requested*** 
 - 6 - 

 
Collaboration Agreement, the ctDNA Platform Development Program (as defined in the Collaboration Agreement), or the CDx Development Program (as defined in the Collaboration Agreement) (clause
(ii) collectively, “Collaboration Products”) subject to the terms of Section 8.3.5 , and (iii) any other products that the Parties mutually agree to include under this Agreement. The term “Product” shall include
associated Service Activities provided in connection with Sales, [...***...]. For clarity, (a) in vitro diagnostic kit products, (b) companion diagnostic assay products developed by FMI for Third Parties, and (c) any
standalone data or molecular information products (i.e. other than clinical diagnostic testing commercial products), are excluded from the definition of a Product. 
  

	 	1.39	Quality Standards 

 The term “Quality Standards” shall mean (i) FMI’s standard
specifications in accordance with Section 2.3, with respect to the Products and performance of Service Activities, which shall include technical specifications on such Product and standards for the validation of such Product, and (ii) CLIA or
QSR requirements, each as applicable to a Product, and other standards required by Applicable Laws in the Territory. 
  

	 	1.40	Region 

 The term “Region” shall mean the [...***...] Region, the [...***...]
Region, and the Non-Europe Region. 
  

	 	1.41	Regulatory Approval 

 The term “Regulatory Approval” shall mean any approvals, licenses,
registrations or authorizations by any Regulatory Authority, necessary to manufacture, sell, market or import or have imported any Product in the Territory. 
  

	 	1.42	Regulatory Authority 

 The term “Regulatory Authority” shall mean any national, supranational
(e.g., the European Commission, the Council of the European Union, the European Medicines Agency), regional, state or local regulatory agency, department, bureau, commission, council or other governmental entity including the EMA, in any country
involved in the granting of Regulatory Approval for the Product. 
  

	 	1.43	Roche Group 

 The term “Roche Group” shall mean collectively Roche and its Affiliates and
Sublicensees. 
  

	 	1.44	Sales 

 The term “Sales” shall mean, for a Product in a particular period, the sum of (i) and
(ii) : 
  

	 	(i)	the amount stated [...***...] for such period [...***...]. This amount reflects [...***...] in such period reduced by
 [...***...] taken in accordance with [...***...]. By way of example
[...***...] taken in accordance [...***...]: 

	 	(a)	[...***...]. 

	 	(b)	[...***...]. 

	 	(c)	[...***...]. 

	 	(d)	[...***...]. 

	 	(e)	[...***...]. 

 For purposes of clarity, [...***...] shall be excluded from
“Sales.” 
  

	 	(ii)	[...***...]. 

  

	 	1.45	Sublicensee 

 The term “Sublicensee” shall mean a permitted entity to which Roche has licensed
rights in accordance with Section 2.1.2 of this Agreement. 
  

	 	1.46	Tactical Plan 

 The term “Tactical Plan” shall mean the plan describing the tactics and
logistics for marketing, promotion and sale of a Product in a specific country or Region, which shall address matters such as (i) annual minimum amounts of Product to be sold in such country or Region, (ii) details regarding the marketing
support for the Products, and (iii) other activities to be conducted by either Party. 

  
 ***Confidential Treatment
Requested*** 
 - 7 - 

	 	1.47	Territory 

 The term “Territory” shall mean all countries of the world, excluding the FMI
Territory. 
  

	 	1.48	Third Party 

 The term “Third Party” shall mean a person or entity other than (i) FMI or
any of its Affiliates or (ii) a member of the Roche Group. 
  

	 	1.49	US 

 The term “US” shall mean the United States of America and its territories and possessions.

  

	 	1.50	US$ 

 The term “US$” shall mean US dollars. 

 

	 	1.51	Additional Definitions 

 Each of the following definitions is set forth in the Section of this Agreement
indicated below: 
  

			
	 Definition
	  	 Section

	Accounting Period	  	9.1
	Alliance Director	  	4.10
	Arbitration Offer	  	8.3.5
	Arbitration Commencement Date	  	8.3.5
	Average Delivery Time Metric	  	7.5.2.4
	Bankruptcy Code	  	18
	Breaching Party	  	17.2.1
	Business Planning Period	  	7.1
	Chairperson	  	4.2
	Collaboration Agreement	  	Whereas clause
	Collaboration Product	  	1.38
	Consensus Matters	  	4.7.3
	Decision Period	  	12.4
	Dependent Obligation	  	7.5.1.4
	Disclosing Party	  	1.12
	Expert	  	8.3.5
	Extended Period	  	7.4
	Global Cost	  	8.2.1
	Global Test Fixed Fee	  	8.2.1
	Indemnified Party	  	14.3
	Indemnifying Party	  	14.3
	Initial Discussion Period	  	8.3.5
	Initial Term	  	1.4
	Initial Product	  	1.38
	Initiating Party	  	12.4
	Investor Rights Agreement	  	Whereas clause
	IVD Collaboration	  	Whereas clause

  
 - 8 - 

			
	 Definition
	  	 Section

	JOT	  	4.9
	Local Cost	  	8.2.2
	Local Test Fixed Fee	  	8.2.2
	Members	  	4.2
	Minimum Price	  	7.6
	Minimum Revenue Requirements	  	1.1.1.1
	Minimum Transfer Payment	  	17.3.4.3
	NGS	  	7.4
	Non-Breaching Party	  	17.2.1
	Panel	  	8.3.5
	Payment Currency	  	9.3
	Peremptory Notice Period	  	17.2.1
	Precedent Obligation	  	7.5.1.4
	Product Trademark	  	12.2
	Publishing Notice	  	16.4
	Publishing Party	  	16.4
	Qualified Sample	  	7.5.2.4
	Quarterly Average Delivery Time Failure	  	7.5.2.4
	Rebuttal	  	8.3.5
	Receiving Party	  	1.12
	Related Agreements	  	Whereas clause
	Renewal Term	  	1.4
	Roche Transfer Activities	  	17.3.4.3
	ROFN Negotiation Period	  	3
	Royalty Term	  	8.3.1
	Samples	  	17.3.4.3
	Selected Agreement	  	8.3.5
	Settlement	  	12.4
	Service Activities	  	1.14
	Suit Notice	  	12.4
	Supporting Memorandum	  	8.3.5
	Third Party Test Fee	  	8.2.2
	Transaction Agreement	  	Whereas clause
	Universal CDx Product	  	2.2
	US Education Collaboration Agreement	  	Whereas clause

  

	2.	Licenses and Exclusivity 

  

	 	2.1	Licenses 

  

	2.1.1	Patents and Know-How 

 Subject to the terms and conditions of this Agreement, FMI hereby grants to Roche a right
and license, including the right to sublicense solely as permitted in Section 2.1.2, under FMI’s interest in the FMI Patent Rights and FMI Know-How to use, have used, import, have imported, export,

  
 - 9 - 

 
have exported, market, have marketed, distribute, have distributed, sell and have sold Products in the Territory. Subject to Section 2.2, the foregoing license shall be co-exclusive (with FMI)
during the Business Planning Period and exclusive (even as to FMI) following the Business Planning Period. 
  

	2.1.2	Sublicenses 

 The licenses granted by FMI to Roche in Section 2.1.1 and 2.1.3 may be sublicensed by Roche
to any Affiliate of Roche for so long as such Affiliate remains an Affiliate. Any such sublicense automatically terminates if such Affiliate Sublicensee ceases to be an Affiliate of Roche. In addition, the licenses granted by FMI to Roche in
Section 2.1.1 and 2.1.3 (and any sublicense by Roche to an Affiliate of Roche) may be sublicensed (through one or more tiers) by Roche (and its Affiliates) to a Third Party (i) without the prior written consent of FMI in countries where
Roche customarily utilizes such Third Party to conduct commercialization activities on behalf of Roche or its Affiliates or (ii) otherwise with the prior written consent of FMI, not to be unreasonably withheld. Roche shall be liable for any act
or omission of any such Sublicensee that is a breach of any of Roche’s obligations under this Agreement as though the same were a breach by Roche, and FMI shall have the right to proceed directly against Roche without any obligation to first
proceed against such Sublicensee. 
  

	2.1.3	Trademarks 

 Subject to the terms and conditions of this Agreement, FMI hereby grants to Roche a right and
license, including the right to sublicense solely as permitted in Section 2.1.2, under FMI’s interest in the FMI Trademarks to use, have used, import, have imported, export, have exported, market, have marketed, distribute, have distributed,
sell and have sold Products in the Territory. Subject to Section 2.2, the foregoing license shall be co-exclusive (with FMI) during the Business Planning Period and exclusive (even as to FMI) following the Business Planning Period. Such trademark
licenses shall be non-transferable, except that FMI shall have the right to sublicense such rights to its licensees in the FMI Territory, and Roche shall have the right to sublicense such rights to its permitted Sublicensees in the Territory. 

 

	 	2.2	Exclusive Right to Commercialize Products 

 During the Business Planning Period, FMI will continue to be
responsible for and will book all sales of Products in the Territory. 
 After the Business Planning Period, Roche and its Sublicensees shall have the
exclusive right (even as to FMI) to market, distribute and sell Products in the Territory, subject to activities designated for FMI to conduct under a Tactical Plan approved by the JOC. To the extent applicable, the foregoing right shall be subject
to the rights granted under the Existing Third Party Rights. If FMI receives any order from a prospective purchaser located in a country in the Territory, FMI shall promptly refer that order to Roche, and Roche shall process such order for such
purchaser in the Territory in accordance with the terms of this Agreement. If Roche receives any order from a prospective purchaser located in the FMI Territory, then Roche shall promptly refer that order to FMI. The Parties will discuss an
appropriate transition plan for the Existing Third Party Rights. However, after the Business Planning Period, at Roche’s request, and to the extent possible under the Existing Third Party Rights without incurring any termination fee, penalty or
similar fee, FMI will terminate any or all of the Existing Third Party Rights. Notwithstanding the above, if there is any termination fee, penalty or similar fee, Roche shall have the right to pay such termination fee, penalty or similar fee to
terminate any or all of the Existing 

  
 - 10 - 

 
Third Party Rights. Moreover, Roche shall have the right, in coordination with FMI, to engage in negotiations with the Third Parties to which the Existing Third Party Rights pertain, with the
intent of allowing Roche to intervene to terminate such Existing Third Party Rights. 
 Unless otherwise agreed expressly by the Parties, for any companion
diagnostic assay Product that is also for use in indicating a therapeutic or referencing a clinical trial of a Third Party (“Universal CDx Product”), such Third Party shall have the right to recommend use of such Universal CDx
Product in the Territory to the extent allowable under Applicable Law, including using or referencing such Universal CDx Product name, logo and trade dress in such Third Party therapeutics label, package insert, or in its promotional and regulatory
materials. 
  

	 	2.3	Product Specifications; Modifications 

 Product specifications for the Initial Products are attached
hereto as Appendix 2.3. FMI will develop product specifications for all other Products during development of each such Product. FMI will provide a copy of draft product specifications to the JOC for all other Products as such specifications are
substantially completed. FMI will provide a copy of any material modifications to any Product specifications to the JOC no less than [...***...] prior to anticipated locking of the design file, unless such changes are reasonably required to be
implemented on an expedited basis, for example, to maintain compliance with Applicable Laws or the requirements of any Regulatory Authority, in which case FMI shall provide such specifications to the JOC as far in advance of implementation as is
reasonably practicable. FMI shall consider in good faith any and all comments or concerns timely raised by Roche in connection with its review of such draft specifications or such modifications. FMI has final authority to adopt specifications for
the Products and modifications thereto, [...***...]. 
  

	3.	Right to Include Future Products 

 During the Agreement Term, Roche shall have a first right to negotiate
with FMI to include in the Territory future clinical diagnostic testing commercial products Controlled by FMI (excluding (i) in vitro diagnostics kit products, (ii) any companion diagnostic assay products developed by FMI for a
Third Party, and (iii) any standalone data or molecular information products (i.e. other than clinical diagnostic testing commercial products)), as a Product to market, distribute and sell in the Territory, on terms to be mutually agreed upon
by the Parties. If FMI plans to Commercially Launch a clinical diagnostic testing commercial product in the Territory or grant such product rights to a Third Party, then FMI shall provide Roche with written notice of such plan and a copy of draft
specifications for such Product. [...***...]. 
  

	4.	Governance 

  

	 	4.1	Joint Management Committee 

 The roles and responsibilities of the JMC are set forth in the Collaboration
Agreement. 
  

	 	4.2	Joint Operational Committee 

 The JOC serves to oversee all activities under this Agreement. The JOC will
strive to reach consensus on any matters within its authority with each Party having one (1) vote. The JOC will reasonably consider all information, proposals and advice received from each Party in relation to the matters for which it has
responsibility. Unresolved disputes at the JOC will be escalated to the JMC using the procedures outlined in the Collaboration Agreement. 

  
 ***Confidential Treatment
Requested*** 
 - 11 - 

	 	4.3	Members 

 The JOC shall be composed of an equal number of persons from each Party
(“Members”). Roche and FMI each shall be entitled to appoint three (3) Members with appropriate seniority and functional expertise, unless otherwise agreed by the Parties. Each Party may replace any of its Members and appoint a
person to fill the vacancy arising from each such replacement. A Party that replaces a Member shall notify the other Party at least [...***...] prior to the next scheduled meeting of the JOC. Both Parties shall use reasonable efforts to keep
an appropriate level of continuity in representation. Both Parties may invite a reasonable number of additional experts and/or advisors to attend part of or the whole JOC meeting with prior notification to the JOC. Members may be represented at any
meeting by another person designated by the absent Member. The JOC shall be chaired [...***...], and then alternating between the Parties on a [...***...] basis thereafter (“Chairperson”). 

 

	 	4.4	Responsibilities of the JOC 

 The JOC shall have the responsibility and authority to: 

 

	(a)	create and approve a transition plan for Existing Third Party Rights; 

  

	(b)	review and recommend for approval by the JMC Tactical Plans and Post Approval Plans for Products that Roche intends to Commercially Launch or has Commercially Launched; 

 

	(c)	review and recommend for approval by the JMC any revisions to the Tactical Plans and Post Approval Plans; 

  

	(d)	review and oversee execution of the Tactical Plans and Post Approval Plans; 

  

	(e)	establish timelines for the Commercial Launch of any Products and the marketing, distribution and sale of such Products; 

  

	(f)	identify appropriate resources necessary to conduct the Tactical Plans and Post Approval Plans; 

  

	(g)	create, oversee or disband JOTs as deemed appropriate; 

  

	(h)	establish and set expectations and mandates for JOTs, if applicable; 

  

	(i)	resolve disputes of the ESWG (as such term is defined in the US Education Collaboration Agreement) in accordance with Section 2.2.3 of the US Education Collaboration Agreement; 

 

	(j)	monitor and implement plans to ensure adequate Product supply in the Territory; 

  

	(k)	review and approve product and corporate level branding for Products subject to Section 12.2 (Trademarks & Labeling); 

  

	(l)	[...***...]; 

  

	(m)	review and recommend for approval by the JMC promotional materials outside of FMI’s approved guidelines; 

  

	(n)	review and recommend for approval by the JMC any clinical research for Products in the Territory; provided that the Parties may conduct clinical research without approval of the JMC in accordance with Section 6.2
(Clinical Trials); 

  

	(o)	[...***...]; 

  
 ***Confidential Treatment
Requested*** 
 - 12 - 

	(p)	recommend action items to its respective decision making bodies; 

  

	(q)	review Quality Standards and modifications thereto in accordance with Section 2.3 (Product Specifications and Modifications); 

  

	(r)	review customer service practices and performance in accordance with Section 7.5.2.3 (Customer Service); 

  

	(s)	review strategies for reimbursement approvals in accordance with Section 6.4 (Reimbursement); 

  

	(t)	review Average Delivery Time Metric in accordance with Section 7.5.2.4; and 

  

	(u)	attempt in good faith to resolve any disputes between the Parties. 

 The JOC shall have no responsibility and
authority other than that expressly set forth in this Section, in the Related Agreements or as otherwise agreed to in writing by both Parties. 
  

	 	4.5	Meetings 

 The Chairperson or his/her delegate will be responsible for sending invitations and agendas
for all JOC meetings to all Members at least [...***...] before the next scheduled meeting of the JOC. The venue for the meetings shall be agreed by the JOC. The JOC shall hold meetings at least [...***...], either in person or by
tele-/video-conference, and in any case as frequently as the Members of the JOC may agree shall be necessary, but not less than [...***...]. The Alliance Director of each Party may attend the JOC meetings as a permanent participant. 

 

	 	4.6	Minutes 

 The Chairperson will be responsible for designating a Member to record in reasonable detail and
circulate draft minutes of JOC meetings to all members of the JOC for comment and review within [...***...] after the relevant meeting. The Members of the JOC shall have [...***...] to provide comments. The Party preparing the minutes
shall incorporate timely received comments and distribute finalized minutes to all Members of the JOC within [...***...] of the relevant meeting. The Chairperson approves the final version of the minutes before its distribution. 

 

	 	4.7	Decisions 

  

	4.7.1	Decision Making Authority 

 The JOC shall decide matters within its responsibilities set forth in
Section 4.4. 
  

	4.7.2	Consensus; Good Faith 

 The Members of the JOC shall act in good faith to cooperate with one another and seek
agreement with respect to issues to be decided by the JOC. The Parties shall endeavor to make decisions by consensus with each Party having one (1) vote. 
  

	4.7.3	Failure to Reach Consensus 

 If the JOC is unable to decide a matter requiring JOC approval by consensus, then
the matter shall be escalated to the [...***...]. 

  
 ***Confidential Treatment
Requested*** 
 - 13 - 

	 	4.8	Information Exchange 

 FMI and Roche shall exchange the information in relation to its activities under
this Agreement through the JOC. FMI and Roche may ask reasonable questions in relation to the above information and offer advice in relation thereto and each Party shall give due consideration to the other Party’s input. The JOC may determine
other routes of information exchange. Notwithstanding anything to the contrary in this Agreement, if FMI, FMI’s Affiliates or sublicensees have sales forces in a country/Region outside of the FMI Territory for a product after the Business
Planning Period, then Roche shall have the right to redact competitively sensitive information, including within the Tactical Plans or Post Approval Plans provided to FMI for any Product in such country/Region. 

 

	 	4.9	Joint Operational Teams 

 The JOC shall have the right to establish joint operational teams
(“JOT”), which shall have the authority granted to them by the JOC and shall be comprised of members from both Parties. 
  

	 	4.10	Alliance Director 

 Each Party shall appoint one person to be its point of contact with responsibility
for facilitating communication and collaboration between the Parties (each, an “Alliance Director”). The Alliance Directors shall be permanent participants of the JOC meetings (but not members of the JOC). The Alliance Directors
shall facilitate resolution of potential and pending issues and potential disputes to enable the JOC to reach consensus and avert escalation of such issues or potential disputes. 

 

	 	4.11	Limitations of Authority 

 The JOC shall have no authority to amend or waive any terms of this Agreement.

  

	 	4.12	Expenses 

 Each Party shall be responsible for its own expenses including travel and accommodation costs
incurred in connection with the JOC. 
  

	 	4.13	Lifetime 

 The JOC shall exist during the Agreement Term. 

 

	5.	Supply 

 Subject to Section 7.5.2.4, FMI shall be solely and exclusively responsible
[...***...] for the commercial supply of Products for sale in the Territory by or on behalf of Roche, and FMI shall use Commercially Reasonable Efforts to provide Products and Service Activities in the amounts requested by Roche meeting the
Quality Standards and Average Delivery Time Metric. 
 For a given Product, if FMI fails to complete the Service Activities associated with such Product in
a manner that meets such Product’s Quality Standards for at least [...***...] of the Qualified Samples received from Roche in the Territory in a given Calendar Quarter (a “Quarterly Quality Standards Failure”) and such
failure exists for [...***...], then prior to the end of such [...***...], the JOC shall prepare a plan for improving such performance, which plan will be implemented in the [...***...]. The JOC will monitor the implementation and
effectiveness of such plan with a goal of achieving and maintaining compliance on a consistent basis for such Quality Standards. If, following the implementation of a plan by the JOC to improve such performance, FMI is unable to improve performance,
and there is a Quarterly Quality Standards Failure for [...***...] (a “Material Performance Standards Failure”), then this shall be considered a material breach of this Agreement by FMI. 

  
 ***Confidential Treatment
Requested*** 
 - 14 - 

 [...***...]. Roche shall have the right, during normal business hours and upon reasonable advanced notice,
to audit any Third Party used by FMI or its Affiliates in the supply of Products and services related to Products to the extent permitted in any existing agreements with such Third Party contractors and in accordance with the terms and conditions of
such agreements. Any new agreements entered into by FMI with respect to commercial supply of Products for sale in the Territory by or on behalf of Roche, shall provide Roche with the right to audit. 

 

	6.	Regulatory 

  

	 	6.1	Responsibility 

 Except as otherwise agreed to by the Parties, FMI, [...***...], shall be
responsible for, in consultation with Roche, and shall use Commercially Reasonable Efforts in the preparation of applications for Regulatory Approvals, as well as all governmental approvals required to market, import, have imported, sell and have
sold Products in the Territory. FMI shall be responsible for pursuing and compiling all regulatory filing documentation, and Roche shall reasonably assist FMI in preparing and submitting such regulatory filing documentation and interacting with
Regulatory Authorities, for Products in the Territory. FMI or its Affiliates shall use Commercially Reasonable Efforts to prepare, or have prepared for it, all regulatory filings and Regulatory Approvals for all Products that are required to be
submitted in each country of the Territory where Roche intends to Commercially Launch a Product or has Commercially Launched a Product. Roche shall reasonably assist FMI in submitting all such regulatory filings and Regulatory Approvals in
FMI’s name, unless prohibited by Applicable Law, in which case, to the extent required under Applicable Law, Roche shall file such regulatory filings and Regulatory Approvals in Roche’s name. Each Party shall promptly supply the other
Party with a copy of all material communications related to a Product to or from any Regulatory Authority in the Territory, including (i) communications with respect to any visits by any governmental authority or Regulatory Authority to any
facilities at which any Product is manufactured or sold in the Territory and (ii) any written or oral inquiries about, any procedures in connection with any Product in the Territory. 

 

	 	6.2	Clinical Trials 

 The Parties shall discuss at the JOC and consider any clinical research (including,
without limitation, any investigator sponsored studies and studies with key opinion leaders) to be conducted for the Products during the Agreement Term that may be necessary or reasonably useful in furtherance of market development and access for
Products in the Territory. Except as otherwise agreed to by the Parties, Roche shall have the right to conduct local clinical studies (including investigator sponsored studies and clinical studies with key opinion leaders) where such clinical
research is for such local country or Region, provided that Roche shall consult with FMI through the JOC and consider in good faith any comments provided by FMI with respect to such strategy and conduct of such local clinical studies,
[...***...] in a given country in the Territory during the Agreement Term. Except as otherwise agreed to by the Parties, with respect to any global clinical studies, FMI shall have the right to conduct, [...***...], and shall be
responsible for the strategy and conduct of such global clinical studies, provided that FMI shall consult with Roche through the JOC and consider in good faith any comments provided by Roche with respect to such strategy and conduct of such global
clinical studies. If the Parties do not mutually agree to conduct additional global clinical research for the Territory, FMI shall have the right, but not the obligation, to pursue such global clinical research in its sole discretion and shall be
responsible for [...***...]. 

  
 ***Confidential Treatment
Requested*** 
 - 15 - 

	 	6.3	Reporting Adverse Events 

 If the development or commercialization or a given Product mandates the mutual
reporting of adverse events, the Parties will establish procedures for tracking and informing each other concerning such adverse advents as required by law, and shall maintain such databases and execute such agreements as needed for this purpose.

  

	 	6.4	Reimbursement 

 Roche will be responsible, [...***...], in cooperation with FMI, for all activities
related to reimbursement approval for Products in the Territory. Prior to submission, Roche shall discuss its proposed filings for reimbursement approval of Products at the JOC and shall consider in good faith any comments provided by FMI with
respect to such filings. After those materials have been submitted to the appropriate pricing authority, Roche shall permit FMI to obtain copies of such materials, including in electronic format, at reasonable times. However, if FMI, FMI’s
Affiliates, or sublicensees have sales forces in a country/Region outside of the FMI Territory for a FMI clinical diagnostic product after the Business Planning Period, then Roche shall have the right to redact from such filings competitively
sensitive information on reimbursement approvals to FMI for any Product in such country/Region. Roche shall use Commercially Reasonable Efforts to file submissions for reimbursement approval in each country where it intends to, or has, Commercially
Launched a Product. For clarity, submissions for reimbursement approval in the Territory shall be consistent with the [...***...] agreed upon by the Parties. 
  

	7.	Commercialization 

  

	 	7.1	Business Planning Period 

 The Parties will use the first [...***...] of the Initial Term (such
[...***...] period the “Business Planning Period”) to explore and develop a plan for the commercialization of the Initial Products by Roche in the Territory. 

During the Business Planning Period, the Parties will focus on an analysis of the market, prioritization of countries and Regions within the Territory with
respect to market access and market development, and in the formation of strategies related to obtaining Regulatory Approval and reimbursement for Products in said prioritized countries and Regions. 

Following the Business Planning Period, the Parties will implement on the strategies agreed to at the JOC and JMC, in a staged approach and according to
detailed Tactical Plans and Post-Approval Plans for each country/Region. Unless otherwise agreed by the Parties, following the Business Planning Period, Roche shall have the exclusive right (even as to FMI) to market, distribute and sell Products in
the Territory in accordance with the terms of this Agreement. Notwithstanding this exclusive right, the JOC shall consider utilizing FMI to conduct certain medical educational and/or medical affairs activities in connection with a Tactical Plan.

  

	 	7.2	Reduction in Scope of Territory 

 During the Business Planning Period, Roche shall have the right to
exclude countries or Regions from the Territory with immediate effect by providing written notice to FMI. Upon delivery of such written notice, the Territory shall be revised to remove such country or Region from the Territory and upon such country
or Region shall be deemed to be included in the FMI Territory. For clarity, 

  
 ***Confidential Treatment
Requested*** 
 - 16 - 

 
upon exclusion of any country or Region by Roche pursuant to this Section 7.2, the licenses and rights granted under this Agreement to Roche with respect to such country or Region, as
applicable, shall automatically terminate and FMI shall have the sole right and discretion with respect to Products in such excluded country or Region. 
  

	 	7.3	Sales 

 Except as otherwise expressly agreed between the Parties, after the Business Planning Period:

  

	 	(a)	Subject to the Existing Third Party Rights, Roche will book all sales of Products in the Territory. 

  

	 	(b)	Subject to the Existing Third Party Rights, Roche will be responsible for billing and collections of Products in the Territory. 

  

	 	7.4	Territory, Initial Launch and Launch Delay Fee 

 Following the Business Planning Period, and subject to
FMI having fulfilled its obligations under this Agreement, if Roche fails to Commercially Launch the Initial Products in a given Region in the Territory in accordance with the schedule below, then Roche shall have the right to pay FMI a Launch Delay
Fee [...***...] (the “Extended Period”). If Roche does not pay the Launch Delay Fee or thereafter Commercially Launch the Initial Products within the Extended Period, then FMI may, in its sole discretion, elect to
(i) convert the licenses under Section 2.1 to non-exclusive, or (ii) terminate the licenses under Section 2.1 and remove the Regions from the Roche Territory (and upon such election such Region shall be deemed to be included in the
FMI Territory) in each case (i) and (ii) other than in any country in such Region where Roche has already Commercially Launched prior to the end of the applicable period or Extended Period): 

[...***...]. 
 For example, [...***...] 

Notwithstanding the foregoing, Roche shall not be required to pay any Launch Delay Fee if such failure to Commercially Launch is a result of FMI failing to
meet its responsibilities under this Agreement, including providing [...***...], and, Roche shall have an automatic extension of the deadline for the amount of time equal to the period in which FMI has not cured such failure before which Roche
is required to launch in a Region. For clarity, upon FMI’s cure of such failure, if Roche fails to meet the extended deadline for Commercial Launch, then Roche shall have the right to pay the Launch Delay Fee and obtain the extension or such
Regions (other than any country in such Regions where Roche has already Commercial Launched) shall be deemed to be included in the FMI Territory. 
  

	 	7.5	Responsibility 

  

	7.5.1	Roche Responsibilities 

  

	7.5.1.1	Funding Commitment 

 Subject to FMI meeting its obligations under this Agreement, during the first
[...***...] of the Initial Term, Roche will commit at least [...***...] in Roche FTE resources (based on Roche’s standard FTE rates as consistently applied). and out-of-pocket expenditures for the activities under this Agreement.
FMI may audit Roche in accordance with Article 11 to ensure compliance with this Section. Notwithstanding the above, if there is a reduction in the scope of the Territory pursuant to Section 7.2, then FMI and Roche shall negotiate in good faith
an adjustment to the [...***...] commitment to equitably reflect the reduction in the market value of the Territory. 

  
 ***Confidential Treatment
Requested*** 
 - 17 - 

	7.5.1.2	Minimum Revenue Requirement 

 Commencing in [...***...], in connection with the review of the
Tactical Plan, [...***...] (the “Minimum Revenue Requirements”). If the Initial Product specifications are modified pursuant to Section 2.3, the JOC may establish new Minimum Revenue Requirements for such Initial Product
for the year in which such modification occurs. Roche will [...***...]. If Roche fails to meet the Minimum Revenue Requirements for an Initial Product in any country in the Territory for [...***...], then FMI will have the right, in its
sole discretion, to either (i) remove such country from the Territory (and upon such election such country shall be deemed to be included in the FMI Territory) or (ii) convert the license for such country to non-exclusive.  

 

	7.5.1.3	Commercial Activities 

 During the Business Planning Period, Roche’s activities shall focus
[...***...]. 
 Throughout the Agreement Term, Roche will be responsible for the preparation of country-or Region-specific Tactical Plans and
Post-Approval Plans for Products in the Territory, which shall be updated [...***...] and submitted to the JOC for review and comment. All activities under this Agreement will be conducted in accordance with country- or Region-specific
Tactical Plans and Post-Approval Plans to be developed by Roche, working in cooperation with FMI, subject to review and approval by the JMC. 
 Roche will
use Commercially Reasonable Efforts to initiate and pursue market development and Commercially Launch Products in the Territory in accordance with the Tactical Plans, Post Approval Plans and the terms of this Agreement. 

 

	7.5.1.4	Equitable Adjustments 

 Where either Roche or FMI has an obligation under this Agreement (each such a
“Dependent Obligation”) that can only reasonably be fulfilled if the other Party first performs one or more of its specific contractual obligations hereunder (each a “Precedent Obligation”), then, any deadline for
the performance by Roche or FMI, as applicable, of such Dependent Obligation shall be tolled (i.e., the deadline shall be extended) for a period of time equal to the delay in the performance by such other Party of the relevant Precedent Obligation.
For avoidance of doubt, each such deadline shall be similarly tolled to the extent achievement of an obligation under this Agreement is prevented by an event of force majeure as and to the extent provided in Section 19.16. 

 

	7.5.2	FMI Responsibilities 

  

	7.5.2.1	Product Training 

 FMI will provide Roche with NGS and Product training using Commercially Reasonable Efforts,
including samples of each related training material used by FMI in the FMI Territory throughout the Term. Such training will be provided in the locations and on the schedule agreed to in the Tactical Plans. Each Party shall be responsible for their
respective costs in relation thereto. For clarity, FMI trainers will provide this training at no charge to Roche. 

  
 ***Confidential Treatment
Requested*** 
 - 18 - 

	7.5.2.2	Materials 

 [...***...], or more frequently when available throughout the Term, FMI will provide Roche
with copies of its then current Product marketing material, and will share with Roche any Product brand, promotional, or similar plans, any market research plans and results, any educational materials or other information or analysis prepared by or
for FMI related to the Products in the FMI Territory or in the Territory. 
 Unless otherwise agreed between the Parties, after the Business Planning
Period, FMI will be responsible for Product sequencing, analysis and reporting services in accordance with the NGS Sequencing, Analysis and Reporting section below. 
  

	7.5.2.3	Customer Service 

 During the Business Planning Period, the JOC shall discuss and determine the reasonable
levels of customer service assistance in addressing sales and technical support issues, customer inquiries, defective product and service replacements to be provided by the Parties in each country in the Territory consistent with the Tactical Plans,
including in which local country languages and manner such customer service shall be provided. [...***...]. FMI shall provide Roche with [...***...] reports summarizing customer service assistance requests and inquiries (including a
breakdown by percentage of the general issues or complaints raised by customers for each country). 
  

	7.5.2.4	NGS Sequencing and Supply of Products and Service Activities 

 FMI shall use Commercially Reasonable Efforts to
provide Roche with the Service Activities (including NGS sequencing) necessary for Roche to implement the Tactical Plan and to meet the commercial need for Products sold by Roche in the Territory. Such Service Activities will meet the Quality
Standards and the Average Delivery Time Metric. In the event of a shortfall/limited capacity of Products or Service Activities needed by both FMI and Roche, such available capacity shall be distributed [...***...] with respect to the
then-current volume used by each Party. 
 For each Product, FMI will provide the JOC with the average time between receipt by FMI of a processable sample
meeting minimum tissue or other specimen requirements as set forth in FMI’s standard operating procedures (such sample, a “Qualified Sample”) and delivery by FMI of the results of testing for such Product (the “Average
Delivery Time Metric”). Such Average Delivery Time Metric will initially be [...***...] days for FoundationOne® and [...***...] days for FoundationOne® Heme. After the Business Planning Period and periodically
thereafter, the Average Delivery Time Metric may be revised by mutual written agreement of the Parties for differences in logistical, regulatory and other relevant factors. For a given Product, if FMI fails to achieve the Average Delivery Time
Metric for at least [...***...] of the Qualified Samples received from Roche in the Territory in [...***...] Calendar Quarter (a “Quarterly Average Delivery Time Failure”) and such failure exists [...***...], then
prior to the end of such [...***...], the JOC shall prepare a plan for improving such performance, which plan will be implemented in the [...***...]. The JOC will monitor the implementation and effectiveness of such plan with a goal of
achieving and maintaining compliance on a consistent basis for such Average Delivery Time Metric. If, following the implementation of a plan by the JOC to improve such performance, FMI is unable to improve performance, and there is a Quarterly
Average Delivery Time Failure for an additional [...***...] (a “Material Average Delivery Time Failure”), then this shall be considered a material breach of this Agreement by FMI. 

  
 ***Confidential Treatment
Requested*** 
 - 19 - 

 To the extent feasible and permitted by Applicable Law and regulatory guidelines of applicable Regulatory
Authorities, the initial sequencing will be conducted by FMI at FMI’s laboratory and facilities in the US. 
 FMI shall use Commercially Reasonable
Efforts to conduct or have conducted genomic sequencing locally for its Initial Products [...***...] after the Business Planning Period ends. FMI shall provide Roche with a written plan for the set-up of such [...***...] laboratories,
and shall consider Roche’s reasonable comments thereto. FMI shall update Roche on the progress of the establishment of [...***...] testing. Such [...***...] activities shall be provided in at least the same quality and standards as
the [...***...] testing in effect as of the Effective Date. To the extent that local Third Party costs are passed through to Roche, such costs shall be negotiated in good faith and at arms’ length with no benefits being given to FMI to
the advantage or FMI, its Affiliates, sublicensees or customers that cause a disadvantage or do not similarly benefit the Roche Group and its customers. 

FMI will be solely responsible, [...***...], for the establishment of such laboratories and all Regulatory Approvals necessary for the establishment and
operation of such laboratory(ies). Without limiting the foregoing, the Parties expressly acknowledge that FMI may choose to work with [...***...]. 

Unless otherwise expressly agreed by the Parties, data and final analysis, including medical curation and report generation will be conducted by FMI. Final
reports will be provided from FMI in English or in the local language, to the extent requested by Roche and agreed to by FMI. If FMI is unable to provide local sequencing on the timeline set forth in this Section 7.5.2.4, or if FMI is unable to
provide the NGS sequencing necessary to meet Roche’s commercial requirements for a period of [...***...], then the JOC shall meet to determine a plan for improving such performance and the JOC will monitor the implementation and
effectiveness of such plan, and FMI will provide reasonable support, with a goal of ensuring ongoing access to sufficient local sequencing, which may include Roche (itself or with or through a Third Party acceptable to FMI) performing such local
sequencing in a manner approved by FMI that meets FMI’s requirements for performing subsequent Service Activities. 
  

	 	7.6	Branding and Pricing 

 Product branding and corporate-level branding will be discussed and agreed to at
the JOC. The Parties will discuss at the JOC a [...***...] in the Territory (the “[...***...]”). Unless otherwise expressly agreed by the Parties, the list price for each Product in the Territory will be equal to or greater
than the [...***...] for such Product. 
  

	 	7.7	Product Promotional Materials 

 The Parties will collaborate and coordinate around development of any
promotional or educational materials to be utilized for Products in the Territory leveraging FMI’s existing materials. 
 After the Business Planning
Period, Roche shall be responsible for the preparation of all product promotional material for use with the Products by Roche in the Territory. All such Product promotional material shall be consistent with reasonable brand and Product guidelines
provided to Roche by FMI. Any Product promotional materials not consistent with such approved 

  
 ***Confidential Treatment
Requested*** 
 - 20 - 

 
guidelines shall be subject to review and approval by FMI. Notwithstanding the foregoing, any Product promotional guidelines and materials approved by FMI to be used by Roche will be subject to
final review and approval by Roche. 
  

	8.	Payment 

  

	 	8.1	General 

 Except as otherwise expressly provided for in this Agreement, each Party shall bear its own
costs for its activities under this Agreement, including without limitation, in connection with the Tactical Plans. 
  

	 	8.2	Costs of Services 

  

	8.2.1	FMI Service Costs 

 For each Product sold in the Territory, if FMI provides Service Activities for such Product,
at FMI’s laboratories and facilities in the United States, Roche will pay FMI [...***...] (collectively the “Global Cost”) [...***...] (collectively, the “Global Test Fixed Fee”). The Global Test
Fixed Fee for a Product will be calculated on a trailing [...***...] basis, and the Global Test Fixed Fee and calculation shall be provided to Roche within [...***...] after each [...***...] in the Agreement Term, based on the
Global Test Fixed Fee as determined from the preceding [...***...] and [...***...], subject to audit by Roche in accordance with Article 11. 

For each Product sold in the Territory if FMI provides initial sequencing in laboratories and facilities outside of the US, Roche will pay FMI
[...***...] (collectively, the “Local Cost”), plus [...***...] and [...***...] (collectively, the “US Cost”), [...***...] collectively, the “Local Test Fixed Fee”). The Local
Test Fixed Fee for a Product will be calculated on a trailing [...***...] basis, and the Local Test Fixed Fee and calculation shall be provided to Roche within [...***...] after each [...***...] in the Agreement Term, based on the
Local Test Fixed Fee as determined from the preceding [...***...] and fixed for such Calendar Quarter during the Agreement Term, subject to audit by Roche in accordance with Article 11. 

FMI will submit invoices on a [...***...] basis and Roche shall pay all Global Test Fixed Fees and Local Test Fixed Fees within [...***...]
following Roche’s receipt of an invoice for such fees. 
  

	8.2.2	Third Party Service Costs 

 FMI may have all or part of the Service Activities for Products in the Territory
performed by a Third Party subject to the terms and conditions for Third Parties set forth in Section 7.5.2.4 or as otherwise agreed to in writing by Roche. In the event that all or part of the Service Activities are performed by a Third Party,
Roche shall reimburse FMI [...***...] (the “Third Party Test Fee”), provided that (i) such Third Party Test Fees are negotiated in good faith and at arms’ length with no benefits being given to FMI to the advantage
or FMI, its Affiliates, sublicensees or customers that cause a disadvantage or do not similarly benefit the Roche Group and its customers, and (ii) [...***...]. 

Roche shall pay all Third Party Test Fees within [...***...] following Roche’s receipt of an invoice for such fees. 

  
 ***Confidential Treatment
Requested*** 
 - 21 - 

	 	8.3	Royalty Payments and Sales Milestones 

  

	8.3.1	Royalty Term 

 Royalties shall be payable by Roche on [...***...] of Initial Products on an aggregated
basis for all Initial Products commencing on the first commercial sale of an Initial Product and continuing for so long as Roche is selling any Initial Product (“Royalty Term”). 

 

	8.3.2	Royalty Rates 

 The following royalty rates shall apply to the respective tiers of aggregate [...***...]
of Initial Products in the Territory, on an incremental basis, as follows: [...***...]. 
 For example, if [...***...] of an Initial Product in
the Territory, for the first [...***...] in a given [...***...], is [...***...]. 
 If then in the second [...***...] of such
[...***...], the [...***...] of an Initial Product in the Territory is also [...***...] for such [...***...] thus far, [...***...]. 

For the purpose of calculating royalties of a Product, [...***...] and the royalty rates shall be subject to the following adjustments, as applicable:

  

	8.3.3	Third Party Payments 

 In the event that it is necessary for Roche to obtain a license from a Third Party for
Third Party intellectual property rights to use or sell the Product in the Territory following the Effective Date, Roche shall have the right to deduct [...***...] of any consideration actually paid to such Third Party for such license from
the royalties otherwise due and payable by Roche to FMI under this Section 8.3; provided, however, that in no case shall such reduction lower the amount of royalties otherwise payable under this Section 8.3 by more than [...***...].

  

	8.3.4	Sales Milestones 

 Roche will pay a one-time, non-refundable sales milestone payment of Ten Million US Dollars
(US$10,000,000) the first time the aggregate annual Gross Margin of [...***...] in a given Calendar Year first reach One Hundred Million US Dollars (US$100,000,000). [...***...] 

 

	8.3.5	Collaboration Products 

 The financial terms for any Product that is a Collaboration Product (including royalty
rates and sales milestone payments) and the diligence obligations for any such Product (including Commercial Launch obligations and Minimum Revenue Requirements) must be mutually agreed to in writing by the Parties, taking into consideration the
relative contributions made by each Party to the development of such Product, before such Product is included in this Agreement. Following FMI’s decision to Commercially Launch a Collaboration Product in the Territory, FMI shall provide written
notice to Roche, and if the Parties cannot agree to terms and conditions for the inclusion of such Collaboration Product as a Product in this Agreement within [...***...] (the “Initial Discussion Period”), then the Parties
shall each select an independent Third Party expert who is neutral, disinterested and impartial, and has significant relevant experience in the development and commercialization of pharmaceutical products (the “Expert”). Each
Expert will within [...***...] select a [...***...] Expert to form a panel of [...***...] Experts (“Panel”). The date on which such Panel is in place will be the “Arbitration Commencement
Date.” Each Party shall within [...***...] following the Arbitration Commencement Date prepare and deliver to both the Panel and the other Party its proposed financial terms (including royalty rates and sales

  
 ***Confidential Treatment
Requested*** 
 - 22 - 

 
milestone payments) and diligence obligations (including initial launch and minimum revenue requirements) (collectively, the “Arbitration Offer”) to resolve the disputed matter
for such Product and a memorandum (the “Supporting Memorandum”) in support thereof; provided that such Arbitration Offer shall be on the same or substantially similar terms as the last offer made by such Party to the other Party
during the Initial Discussion Period. The Panel will also be provided with a copy of this Agreement. Within [...***...] after receipt of the other Party’s Supporting Memorandum, each Party may submit to the Panel (with a copy to
the other Party) a rebuttal to the other Party’s Supporting Memorandum (a “Rebuttal”), which may include a revision, marked to show changes, of either Party’s proposed terms. Neither Party may have communications
(either written or oral) with the Panel other than for the sole purpose of engaging the Panel or as expressly permitted in this Section 8.3.5. Within [...***...] after the Panel’s receipt of each Party’s Rebuttal (or the
expiration of the period for the Parties to submit a Rebuttal, if earlier), the Panel will select, between the proposals provided by the Parties, the proposal that the Panel believes most accurately reflects an equitable result for FMI and Roche
(the “Selected Agreement”). The Panel shall not have the authority to modify a proposal initially submitted by a Party. The decision of the Panel shall be the sole, exclusive and binding remedy and the Selected Agreement
shall become a binding and enforceable agreement between the Parties. The Panel will have reasonable discretion to request additional information, hold a hearing, and extend the time frame for reaching a decision regarding the dispute at
issue. The Experts’ fees and expenses will be paid by the Party whose proposal is not selected by the Panel. Each Party will bear and pay its own expenses incurred in connection with any proceedings under this Section 8.3.5. 

 

	 	8.4	Disclosure of Payments 

 Each Party acknowledges that the other Party may be obligated to disclose this
financial arrangement, including all fees, payments and transfers of value, as may be advisable or required under Applicable Law. 
  

	9.	Accounting and Reporting 

  

	 	9.1	Timing of Payments 

 Roche shall calculate royalties [...***...] (each being the last day of an
“Accounting Period”) and shall pay royalties on Net Sales within [...***...] after the end of each Accounting Period in which such Net Sales occur. 
  

	 	9.2	Late Payment 

 Any payment under this Agreement that is not paid on or before the date such payment is
due shall bear interest, to the extent permitted by Applicable Law, at [...***...] points above the average one-month Euro Interbank Offered Rate (EURIBOR), as reported by Reuters from time to time, calculated on the number of days such
payment is overdue. 
  

	 	9.3	Method of Payment 

 Royalties on Net Sales and all other amounts payable by Roche hereunder shall be paid
by Roche in US Dollars (the “Payment Currency”) to account(s) designated by FMI. 

  
 ***Confidential Treatment
Requested*** 
 - 23 - 

	 	9.4	Currency Conversion 

 When calculating the Sales of any royalty-bearing Product that occur in currencies
other than the Payment Currency, Roche shall convert the amount of such sales into [...***...] and then into the Payment Currency using [...***...]. 
  

	 	9.5	Reporting 

 With each payment Roche shall provide FMI in writing for the relevant [...***...] on an
aggregated basis for all Initial Products, and thereafter on a Product-by-Product basis, the following information: 
 [...***...]. 

 

	10.	Taxes 

 FMI shall pay all sales, turnover, income, revenue, value added, and other taxes levied on
account of any payments accruing or made to FMI under this Agreement. 
 If provision is made in law or regulation of any country for withholding of taxes
of any type, levies or other charges with respect to any royalty or other amounts payable under this Agreement to FMI, then Roche shall promptly pay such tax, levy or charge for and on behalf of FMI to the proper governmental authority, and shall
promptly furnish FMI with receipt of payment. Roche shall be entitled to deduct any such tax, levy or charge actually paid from royalty or other payment due FMI or be promptly reimbursed by FMI if no further payments are due to FMI. Each Party
agrees to reasonably assist the other Party in claiming exemption from such deductions or withholdings under double taxation or similar agreement or treaty from time to time in force and in minimizing the amount required to be so withheld or
deducted. 
  

	11.	Auditing 

  

	 	11.1	Right to Audit 

 Each Party shall keep, and shall require its Affiliates and sublicensees/Sublicensees to
keep, full, true and accurate books of account containing all particulars that may be necessary for the purpose of calculating all amounts payable under this Agreement, such as with respect to royalties in the case of Roche and Cost of Services in
the case of FMI. Such books of accounts shall be kept at their principal place of business. At the expense of the auditing Party, the auditing Party shall have the right to engage an independent public accountant from a major, internationally
recognized accounting firm, to perform, on behalf of the auditing Party an audit of such books and records of the audited Party and its Affiliates, its licensees and sublicensees/Sublicensees, that are deemed necessary by the auditing Party’s
independent public accountant for the period or periods requested by auditing Party and the correctness of any financial report or payments made under this Agreement. 

Upon timely request and at least [...***...] prior written notice from the auditing Party, such audit shall be conducted in the countries specifically
requested by the auditing Party, during regular business hours in such a manner as to not unnecessarily interfere with the audited Party’s normal business activities, and shall be limited to results in the [...***...] prior to audit
notification. 

  
 ***Confidential Treatment
Requested*** 
 - 24 - 

 Such audit shall not be performed more frequently than [...***...] nor more frequently than
[...***...] with respect to records covering any specific period of time. 
 All information, data documents and abstracts herein referred to shall be
used only for the purpose of verifying statements, shall be treated as the audited Party’s Confidential Information subject to the obligations of this Agreement and need neither be retained more than [...***...] after completion of an
audit hereof, if an audit has been requested; nor more than [...***...] from the end of the [...***...] to which each shall pertain; nor more than [...***...] after the date of termination of this Agreement. 

 

	 	11.2	Audit Reports 

 The auditors shall only state factual findings in the audit reports and shall not
interpret the Agreement. The auditors shall share all draft audit reports with the audited Party before the draft report is shared with the auditing Party and before the final document is issued. The final audit report, if any, shall be shared with
the audited Party at the same time it is shared with the auditing Party. 
  

	 	11.3	Over-or Underpayment 

 If the audit reveals an overpayment, such overpayment shall be credited against
future payments owed by Roche for the amount of the overpayment or, if no further payments are owed by Roche, then FMI shall reimburse Roche for the amount of the overpayment within [...***...]. If the audit reveals an underpayment, Roche
shall make up such underpayment with the next payment or, if no further payments are owed by Roche, Roche shall reimburse FMI for the amount of the underpayment within [...***...]. The audited Party shall pay for the audit costs if the
underpayment/over receipt of the audited Party exceeds [...***...] of the aggregate amount of payments owed with regard to the statements subject of the audit. Section 9.2 shall apply to this Section 11.3. 

 

	 	11.4	Duration of Audit Rights 

 The failure of FMI to request verification of any royalty calculation within
the period during which corresponding records must be maintained under this Article 11 will be deemed to be acceptance of the royalty payments and reports. 
  

	12.	Intellectual Property 

  

	 	12.1	Ownership of Inventions 

 Ownership of Inventions shall be as set forth in the Collaboration Agreement.

  

	 	12.2	Trademarks and Labeling 

 The Parties shall attempt to use a uniform global trademark and logo for the
Product; provided, that each Party may use its own trademarks and housemarks as it selects to promote the sale of the Product in the FMI Territory, with respect to FMI, and the Territory, with respect to Roche (collectively, excluding the
housemarks, the “Product Trademarks”). The Parties shall agree on at least [...***...] Product Trademarks for each Product, with [...***...] of the trademarks being the global trademark and the other(s) being trademarks
to be held in reserve in case the global trademark cannot be used in [...***...] or more countries. The placement and size of a Party’s housemarks relative to Product Trademarks shall be approved by the JOC. Excluding the Roche
housemarks, FMI shall own any global Product Trademarks used on or in connection with Products in the Territory, and shall, at its sole cost, be responsible for procurement, maintenance, enforcement and defense of such global Product Trademarks.

  
 ***Confidential Treatment
Requested*** 
 - 25 - 

 Roche shall own its trademarks, including the Roche trademark and hexagon, and may use the Roche trademarks in
connection with the Product as set forth in this Section. FMI shall not file any identical registrations or other filings in respect of any such housemarks owned by Roche. FMI shall own its housemark and any trademark it selects to promote the sale
of the Product in the FMI Territory. Roche shall not file any identical registrations or other filings in respect of any such trademarks and housemarks owned by FMI. 

Each Party shall maintain all registrations of such Product Trademarks owned by it and the other Party shall not file any registrations or other filings in
respect of any of such Product Trademark owned by the Product Trademark owning Party without the Product Trademark owning Party’s prior written consent. FMI shall use Commercially Reasonable Efforts to obtain and maintain Product Trademarks and
to take reasonable measures to enforce oppositions and litigations in relation to the Product Trademarks. 
 Each Party shall use the Product Trademarks in
accordance with sound trademark and trade name usage principles and in accordance with all Applicable Law as reasonably necessary to maintain the validity and enforceability of the Product Trademarks. Each Party recognizes that the trademarks owned
by the other Party represents a valuable asset of such other Party, and that substantial recognition and goodwill are associated with such name, logo and trademarks. Each Party hereby agrees that, without prior written authorization of the other
Party or as specifically permitted in this Agreement, it shall not use such other Party’s trademarks for any purpose. 
 Each Party shall have the
right to police its own trademarks and enforce its own trademarks. Each Party shall have the right to audit the other Party, its Affiliates, sublicensees/Sublicensees and contractors to ensure the quality of the Products to which the trademark is
associated. 
 In the event either Party becomes aware of any infringement of any Product Trademark by a Third Party, such Party shall promptly notify the
other Party and the Parties shall consult with each other and jointly determine the best way to prevent such infringement. 
  

	 	12.3	Prosecution of Patent Rights 

 Patent Rights shall be prosecuted as set forth in the Collaboration
Agreement. 
  

	 	12.4	Patent Coordination Team 

 The JPT as defined in the Collaboration Agreement will address all issues
related to Patent Rights. 
  

	 	12.5	Infringement 

 Infringement shall be addressed as set forth in the Collaboration Agreement. However, if
Roche is commercializing a Product in a particular country in the Territory, then Roche shall have the first right to enforce Patent Rights in such country in the Territory. 
  

	 	12.6	Defense 

 If an action for infringement is commenced against either Party, its licensees or its
sublicensees/Sublicensees, the provisions of the Collaboration Agreement shall apply. 

  
 - 26 - 

	 	12.7	Common Interest Disclosures 

 With regard to any information or opinions disclosed pursuant to this
Agreement by one Party to each other regarding intellectual property and/or technology owned by Third Parties, the Parties agree that they have a common legal interest in determining whether, and to what extent, Third Party intellectual property
rights may affect the conduct of the activities under this Agreement. Accordingly, the provisions of the Collaboration Agreement shall apply in this regard. 
  

	13.	Representations and Warranties 

  

	 	13.1	FMI Representations and Warranties 

  

	13.1.1	Safety Data 

 FMI warrants and represents that it has, and covenants that it will, continue to disclose to Roche
as soon as possible during the Term (i) the results of all preclinical testing and human clinical testing Controlled by FMI relating to any Product and (ii) all information in its Control concerning side effects, injury, toxicity or
sensitivity reaction and incidents or severity thereof with respect to any Product. 
  

	13.1.2	Third Party Patent Rights 

 FMI warrants and represents that, as of the Effective Date, it has no knowledge of
the existence of any patent or patent application owned by or licensed to any Third Party that could prevent Roche from making, having made, using, offering for sale, selling or importing Product in the Territory. 

 

	13.1.3	Ownership of Patent Rights 

 With respect to each Product, FMI shall provide Roche with a list of all FMI Patent
Rights in the Territory that could potentially be asserted with respect to the use, sale, offer for sale, import or export of such Product in the Territory. FMI shall then warrant and represent that it is the exclusive owner of all right, title and
interest in, or is the exclusive licensee of, such FMI Patent Rights. 
  

	13.1.4	Ownership of Trademarks 

 FMI warrants and represents that it is the exclusive owner of all right, title and
interest in, or is the exclusive licensee of the trademarks for the Initial Products in the Territory. 
  

	13.1.5	Inventors 

 FMI warrants and represents that for the inventors of the inventions disclosed and/or claimed in the
disclosed FMI Patent Rights, FMI has obtained the assignment of, or a license under, all interest and all rights or licenses thereunder with respect to the FMI Patent Rights necessary to grant the licenses granted hereunder. All of FMI’s
employees, officers and consultants have executed agreements requiring assignment to FMI of all Inventions made by such individuals during the course of and as a result of their association with FMI. 

 

	13.1.6	Grants 

 FMI warrants and represents that to the best of FMI’s knowledge and belief, FMI has the lawful
right to grant Roche and its Affiliates the rights and licenses described in this Agreement. 

  
 - 27 - 

	13.1.7	Valid Claims 

 As of the Effective Date, FMI warrants and represents that it is not in possession of any
information that would, in its reasonable opinion, render invalid and/or unenforceable any claims in any issued patent licensed pursuant to this Agreement. FMI has no knowledge of any inventorship disputes concerning any FMI Patent Rights. 

 

	13.1.8	Ownership and Validity of Know-How 

 As of the Effective Date, FMI warrants and represents that FMI’s
Know-How relating to Products and Service Activities is legitimately in the possession of FMI and has not been misappropriated from any Third Party, and FMI has taken reasonable measures to protect the confidentiality of its Know-How. 

 

	 	13.2	Mutual Representations of the Parties 

  

	13.2.1	Authorization 

 As of the Effective Date, each Party warrants and represents to the other Party that the
execution, delivery and performance of this Agreement by such Party and all instruments and documents to be delivered by such Party hereunder: (i) are within the corporate power of such Party; (ii) have been duly authorized by all
necessary or proper corporate action; (iii) are not in contravention of any provision of the certificate of formation or limited liability company agreement of such Party; (iv) to the knowledge of such Party, will not violate any law or
regulation or any order or decree of any court of governmental instrumentality; (v) will not violate the terms of any indenture, mortgage, deed of trust, lease, agreement, or other instrument to which such Party is a party or by which such
Party or any of its property is bound, which violation would have a material adverse effect on the financial condition of such Party or on the ability of such Party to perform its obligations hereunder; and (vi) do not require any filing or
registration with, or the consent or approval of, any governmental body, agency, authority or any other person, which has not been made or obtained previously (other than approvals required under the HSR Act, Regulatory Approvals required for the
sale of Products and filings with Regulatory Authorities required in connection with Products). 
  

	13.2.2	No Claims 

 As of the Effective Date, each Party warrants and represents to the other Party that there are no
claims or investigations (other than with respect to the Parties’ HSR filings), pending or threatened against such Party or any of its Affiliates, at law or in equity, or before or by any governmental authority relating to the matters
contemplated under this Agreement or that would materially adversely affect such Party’s ability to perform its obligations hereunder. 
  

	13.2.3	No Conflict 

 Each Party warrants and represents that neither it nor any of its Affiliates is or will be under
any obligation to any person, contractual or otherwise, that is conflicting with the terms of this Agreement or that would impede the fulfillment of such Party’s obligations hereunder. 

  
 - 28 - 

	13.2.4	Activities 

 Each Party will perform all activities under this Agreement (i) in a professional manner,
(ii) in conformance with the level or care and skill ordinarily exercised by other professional institutions in similar circumstances, and (iii) in compliance with Applicable Law. 

 

	14.	Indemnification 

  

	 	14.1	Indemnification by Roche 

 Roche shall indemnify, hold harmless and defend FMI and its Affiliates, and
their respective directors, officers, employees, independent contractors, and agents from and against any and all losses, expenses, cost of defense (including without limitation attorneys’ fees, witness fees, damages, judgments, fines and
amounts paid in settlement) and any amounts FMI becomes legally obligated to pay because of any claim or claims brought by a Third Party against it to the extent that such claim or claims arise out of any member of the Roche Group’s action or
inactions in connection with activities under this Agreement, except to the extent such losses, expenses, costs and amounts are due to the gross negligence or willful misconduct or failure to act of FMI. 

 

	 	14.2	Indemnification by FMI 

 FMI shall indemnify, hold harmless and defend Roche and its Affiliates, and
their respective directors, officers, employees, independent contractors and agents from and against any and all losses, expenses, cost of defense (including without limitation attorneys’ fees, witness fees, damages, judgments, fines and
amounts paid in settlement) and any amounts Roche becomes legally obligated to pay because of any claim or claims brought by a Third Party against it to the extent that such claim or claims arise out of FMI’s and its Affiliates’ actions or
inactions in connection with activities under this Agreement, except to the extent such losses, expenses, costs and amounts are due to the gross negligence or willful misconduct or failure to act of Roche. 

 

	 	14.3	Procedure 

 In the event of a claim by a Third Party against a Party entitled to indemnification under
this Agreement (“Indemnified Party”), the Indemnified Party shall promptly notify the other Party (“Indemnifying Party”) in writing of the claim and the Indemnifying Party shall undertake and solely manage and
control, at its sole expense, the defense of the claim and its settlement. The Indemnified Party shall cooperate with the Indemnifying Party and may, at its option and expense, be represented in any such action or proceeding by counsel of its
choice. The Indemnifying Party shall not be liable for any litigation costs or expenses incurred by the Indemnified Party without the Indemnifying Party’s written consent. The Indemnifying Party shall not settle any such claim unless such
settlement fully and unconditionally releases the Indemnified Party from all liability relating thereto, unless the Indemnified Party otherwise agrees in writing. 
  

	15.	Liability 

  

	 	15.1	Disclaimer 

 EXCEPT AS EXPRESSLY PROVIDED IN THIS AGREEMENT, NEITHER PARTY PROVIDE ANY WARRANTIES,
WHETHER WRITTEN OR ORAL, EXPRESS OR IMPLIED. FMI AND ROCHE DISCLAIM ALL OTHER WARRANTIES, WHETHER EXPRESS OR IMPLIED, WITH RESPECT TO EACH OF THEIR RESEARCH, DEVELOPMENT AND COMMERCIALIZATION 

  
 - 29 - 

 
EFFORTS HEREUNDER, INCLUDING, WITHOUT LIMITATION, WHETHER THE PRODUCTS CAN BE SUCCESSFULLY DEVELOPED OR MARKETED, THE ACCURACY, PERFORMANCE, UTILITY, RELIABILITY, TECHNOLOGICAL OR COMMERCIAL
VALUE, COMPREHENSIVENESS, MERCHANTABILITY OR FITNESS FOR ANY PARTICULAR PURPOSE WHATSOEVER OF THE PRODUCTS. EXCEPT IN THE CASE OF A BREACH OF ARTICLE 16, AND WITHOUT LIMITING THE PARTIES’ OBLIGATIONS UNDER ARTICLE 14, IN NO EVENT SHALL EITHER
FMI OR ROCHE BE LIABLE FOR SPECIAL, INDIRECT, INCIDENTAL OR CONSEQUENTIAL DAMAGES ARISING OUT OF THIS AGREEMENT BASED ON CONTRACT, TORT OR ANY OTHER LEGAL THEORY. 
  

	16.	Obligation Not to Disclose Confidential Information 

  

	 	16.1	Non-Use and Non-Disclosure 

 During the Agreement Term and for [...***...] thereafter, a Receiving
Party shall (i) treat Confidential Information provided by Disclosing Party as it would treat its own information of a similar nature, (ii) take all reasonable precautions not to disclose such Confidential Information to Third Parties,
without the Disclosing Party’s prior written consent, and (iii) not use such Confidential Information other than for fulfilling its obligations under this Agreement. If any Confidential Information is required to be disclosed by the
Receiving Party or its Affiliates to comply with a court or administrative order, the Receiving Party or its Affiliates will provide prompt notice to the Disclosing Party to enable the Disclosing Party to resist such disclosure. 

 

	 	16.2	Permitted Disclosure 

 Notwithstanding the obligation of non-use and non-disclosure set forth in
Section 16.1, the Parties recognize the need for certain exceptions to this obligation, specifically set forth below, with respect to press releases, patent rights, publications, and certain commercial considerations. 

 

	 	16.3	Press Releases 

 Each Party shall provide the other with a copy of any draft press release related to the
activities contemplated by this Agreement at least [...***...] prior to its intended publication for such other Party’s review. The reviewing Party may provide the releasing Party with suggested modification to the draft press release.
The releasing Party shall consider, and shall not unreasonably disregard, the reviewing Party’s suggestions in issuing its press release. 
  

	 	16.4	Publications 

 During the Agreement Term, the following restrictions shall apply with respect to
disclosure by any Party of Confidential Information relating to the Product in any publication or presentation: 
  

	a)	Both Parties acknowledge that it is their policy for the studies and results thereof to be registered and published in accordance with their internal guidelines. The Parties shall have the right to jointly publish all
studies, clinical trials and results conducted or generated in accordance with this Agreement to the extent both Parties have jointly participated in or collaborated in such clinical study or trial. To the extent any study or clinical trial is
conducted solely by Roche with no participation by FMI, Roche, in accordance with its internal policies and procedures, shall have the right to publish all such studies, clinical trials and results thereof on the clinical trial registries that are
maintained by or on behalf of Roche, and FMI shall not publish any such studies, clinical trials or results thereof on its clinical trial registry, provided however, the Roche’s clinical trial registry can be accessed via a link from FMI’s
clinical trial registry. 

  
 ***Confidential Treatment
Requested*** 
 - 30 - 

	b)	A Party (“Publishing Party”) shall provide the other Party with a copy of any proposed publication or presentation at least [...***...] prior to submission for publication so as to provide such
other Party with an opportunity to recommend any changes it reasonably believes are necessary to continue to maintain the Confidential Information disclosed by the other Party to the Publishing Party in accordance with the requirements of this
Agreement. The incorporation of such recommended changes shall not be unreasonably refused; and if such other Party notifies (“Publishing Notice”) the Publishing Party in writing, within [...***...] after receipt of the copy
of the proposed publication or presentation, that such publication or presentation in its reasonable judgment (i) contains an invention, solely or jointly conceived and/or reduced to practice by the other Party, for which the other Party
reasonably desires to obtain patent protection or (ii) could be expected to have a material adverse effect on the commercial value of any Confidential Information disclosed by the other Party to the Publishing Party, the Publishing Party shall
prevent such publication or delay such publication for a mutually agreeable period of time. In the case of inventions, a delay shall be for a period reasonably sufficient to permit the timely preparation and filing of a patent application(s) on such
invention, and in no event less than [...***...] from the date of the Publishing Notice. 

  

	 	16.5	Commercial Considerations 

 Nothing in this Agreement shall prevent a Party or its Affiliates from
disclosing Confidential Information of the other Party to (i) governmental agencies to the extent required or desirable to secure government approval for the manufacture or sale of Product in the Territory, and (ii) Third Parties acting on
behalf of Roche, to the extent reasonably necessary to conduct the activities contemplated by this Agreement, provided such Third Parties are bound by confidentiality and non-use obligations with respect to such information that are no less
stringent than those included in this Agreement. The Receiving Party may disclose Confidential Information of the Disclosing Party to the extent that such Confidential Information is required to be disclosed by the Receiving Party to comply with
Applicable Law, to defend or prosecute litigation or to comply with governmental regulations, provided that the Receiving Party provides prior written notice of such disclosure to the Disclosing Party and, to the extent practicable, takes reasonable
and lawful actions to minimize the degree of such disclosure 
  

	17.	Term and Termination 

  

	 	17.1	Commencement and Term 

 This Agreement shall commence upon the Effective Date and continue for the
Agreement Term. 
  

	 	17.2	Termination 

  

	17.2.1	Automatic Termination 

 This Agreement shall terminate automatically, without any notice or other action by any
Party, upon the first to occur of (i) termination of the Transaction Agreement in accordance with its terms and (ii) the mutual written consent of the Parties. 
  

	17.2.2	Termination for Breach 

 A Party (“Non-Breaching Party”) shall have the right to
terminate this Agreement in its entirety or on a country-by-country or Product-by-Product basis in the event the other Party (“Breaching 

  
 ***Confidential Treatment
Requested*** 
 - 31 - 

 
Party”) is in breach of any of its material obligations under this Agreement. The Non-Breaching Party shall provide written notice to the Breaching Party, which notice shall identify
the breach and, if applicable, the affected countries in which, and the affected Products with respect to which, the Non-Breaching Party intends to have this Agreement terminate. The Breaching Party shall have a period of [...***...] after
such written notice is provided (“Peremptory Notice Period”) to cure such breach. If the Breaching Party has a dispute as to whether such breach occurred or has been cured, it will so notify the Non-Breaching Party, and the
expiration of the Peremptory Notice Period shall be tolled until the Parties agree or the arbitrators have determined in accordance with Section 19.3 that this Agreement was materially breached. It is understood and acknowledged that, during
the pendency of such a dispute, all of the terms and conditions of this Agreement shall remain in effect, and the Parties shall continue to perform all of their respective obligations under this Agreement. Upon such agreement or determination of
material breach or failure to cure, the Breaching Party may have the remainder of the Peremptory Notice Period to cure such breach. If such breach is not cured within the Peremptory Notice Period, then absent withdrawal of the Non-Breaching
Party’s request for termination, this Agreement shall terminate in accordance with the written notice provided by the Non-Breaching Party and such termination shall be effective as of the expiration of the Peremptory Notice Period. For clarity,
Roche may terminate this Agreement under this Section 17.2.2 if there is a material diminution in the Quality Standards, except as permitted under Section 2.3, or if FMI is unwilling or unable to fulfill its obligations under
Section 7.5.2, and FMI may terminate this Agreement under this Section 17.2.2 if Roche is unwilling or unable to fulfill its obligations under Section 7.5.1. Notwithstanding the foregoing, Roche may terminate this Agreement under this
Section 17.2.2 if a Material Average Delivery Time Failure or Material Performance Standards Failure occurs by providing written notice to FMI within [...***...] of such Material Average Delivery Time Failure or Material Performance
Standards Failure, and no cure period as provided under this Section 17.2.2 shall be applicable for such termination. 
  

	17.2.3	Insolvency 

 A Party shall have the right to terminate this Agreement, if the other Party incurs an Insolvency
Event; provided, however, in the case of any involuntary bankruptcy proceeding, such right to terminate shall only become effective if the Party that incurs the Insolvency Event consents to the involuntary bankruptcy or such proceeding is not
dismissed within [...***...] after the filing thereof. 
  

	17.2.4	Termination by Roche without a Cause 

 Roche shall have the right to terminate this Agreement at any time after
the Initial Term on a Product-by-Product and/or country-by-country basis upon [...***...] prior written notice. The effective date of termination under this Section 17.2.4 shall be the date [...***...] after Roche provides such written
notice to FMI. 
  

	 	17.3	Consequences of Termination and Expiration 

  

	17.3.1	Termination by FMI for Breach by Roche or by Roche without a Cause, or Expiration of the Agreement Term. 

 Upon
any termination under Section 17.2.1, FMI for breach by Roche in accordance with Section 17.2.2, termination by Roche under Section 17.2.4, or upon expiration of the Agreement Term, the following shall apply: 

 

	a)	The rights and licenses granted by FMI to Roche under this Agreement shall terminate in their entirety or on a country-by-country basis, as applicable, on the effective date of termination. 

  
 ***Confidential Treatment
Requested*** 
 - 32 - 

	b)	After the effective date of termination Roche shall, to the extent Roche has the right to do so, assign and transfer to FMI all regulatory filings and Regulatory Approvals, all final pre-clinical and clinical study
reports and clinical study protocols, and all data, including clinical data, in Roche’s possession and control related to Product(s) in the country necessary for FMI to continue to commercialize the Product(s). All data shall be transferred in
the form and format in which it is maintained by Roche. Original paper copies shall only be transferred, if legally required. Roche shall not be required to prepare or finalize any new data, reports or information solely for purposes of transfer to
FMI. 

  

	c)	Roche shall assign all clinical trial agreements, to the extent such agreements have not been cancelled and are assignable without Roche paying any consideration or commencing litigation in order to effect an assignment
of any such agreement. 

  

	d)	FMI shall, upon transfer, have the right to disclose such filings, approvals and data to (i) governmental agencies of the country to the extent required or desirable to secure government approval for the sale of
Product(s) in the country, (ii) Third Parties acting on behalf of FMI, its Affiliates or licensees, to the extent reasonably necessary for the sale of Product(s) in the country, and (iii) Third Parties to the extent reasonably necessary to
market Product(s) in the country. 

  

	17.3.2	Termination by Roche for Breach by FMI or FMI Insolvency 

 Upon a material breach of a material obligation under
this Agreement by FMI pursuant to Section 17.2.1 or FMI’s Insolvency pursuant to Section 17.2.2, at Roche’s option, (i) Roche may seek damages via arbitration under Section 19.3 or (ii) as Roche’s exclusive remedy
(other than for breach of confidentiality under Section 16) FMI shall pay to Roche either a one-time payment reflecting the value of the terminated Product(s) or a royalty on sales of such terminated Product(s) based on the royalty that Roche
would have paid to FMI had the Agreement not terminated, the amount of which will be agreed to by the Parties negotiating in good faith. If the Parties cannot agree on the amount in clause (ii) above, then the determination of such amount shall
be referred to a Panel in a manner analogous to that found in Section 8.3.5. 
 Upon any termination by Roche for breach by FMI in accordance with
Section 17.2.1 or for FMI’s insolvency in accordance with Section 17.2.2, the following shall apply: 
  

	 	a)	the rights and licenses granted by FMI to Roche under this Agreement shall terminate in their entirety or on a country-by-country and Product-by-Product basis, as applicable, on the effective date of termination.

  

	 	b)	After the effective date of termination Roche shall, to the extent Roche has the right to do so, assign and transfer to FMI all regulatory filings and Regulatory Approvals, all final pre-clinical and clinical study
reports and clinical study protocols, and all data, including clinical data, in Roche’s possession and control related to Product(s) in the country necessary for FMI to continue to commercialize the Product(s). All data shall be transferred in
the form and format in which it is maintained by Roche. Original paper copies shall only be transferred, if legally required. Roche shall not be required to prepare or finalize any new data, reports or information solely for purposes of transfer to
FMI. 

  
 - 33 - 

	 	c)	Roche shall assign all clinical trial agreements, to the extent such agreements have not been cancelled and are assignable without Roche paying any consideration or commencing litigation in order to effect an assignment
of any such agreement. 

  

	 	d)	FMI shall, upon transfer, have the right to disclose such filings, approvals and data to (i) governmental agencies of the country to the extent required or desirable to secure government approval for the sale of
Product(s) in the country, (ii) Third Parties acting on behalf of FMI, its Affiliates or licensees, to the extent reasonably necessary for the sale of Product(s) in the country, and (iii) Third Parties to the extent reasonably necessary to
market Product(s) in the country. 

  

	17.3.3	Direct License 

 Upon termination of this Agreement pursuant to Sections 17.2.2 or 17.2.3, with respect to any
existing, permitted sublicense granted by Roche under Section 2.1.2(ii) of this Agreement (and any further sublicenses thereunder) upon the written request of Roche, (i) if the sublicense was consented to by FMI or is to Chugai, then the
sublicense shall survive termination provided such Sublicensee (a) is not then in breach of its sublicense agreement and (b) such Sublicensee agrees to be bound to FMI under the terms and conditions of such sublicense agreement, and
(ii) if the sublicense was not consented to by FMI, then FMI shall negotiate in good faith with the applicable Sublicensee the terms under which such sublicense shall survive such termination, provided that (a) such Sublicensee is not then
in breach of its sublicense agreement (and, in the case of termination by FMI for breach by Roche, that such Sublicensee and any further sublicensees did not cause the breach that gave rise to the termination by FMI); and (b) such Sublicensee
agrees to be bound to FMI under the terms and conditions of such sublicense agreement. 
  

	17.3.4	Other Obligations 

  

	17.3.4.1	Obligations Related to Ongoing Activities 

 Upon the effective date of termination of this Agreement, each Party
(a) shall have the right to cancel all ongoing obligations as of the effective date of termination and (b) shall complete all non-cancellable obligations at its own expense. 

From the date of notice of termination until the effective date of termination, Roche and FMI shall each continue their activities, including preparatory
activities, ongoing as of the date of notice of termination. However, neither Party shall be obliged to initiate any new activities not ongoing at the date of notice of termination. 

After the effective date of termination, neither Party shall have an obligation to perform and/or complete any activities or to make any payments for
performing or completing any activities after such effective date of termination under this Agreement, except as expressly stated herein. 

  
 - 34 - 

 Notwithstanding the foregoing, (a) in case of termination by FMI under Section 17.2.2 or 17.2.3 or by
Roche under Section 17.2.4, upon the request of FMI, Roche shall complete any clinical studies related to the Product(s) that are being conducted by Roche for the Product(s) and are ongoing as of the effective date of termination, and (b) in
case of termination by Roche under Section 17.2.2 or 17.2.3, upon the request of Roche, FMI shall complete any clinical studies related to the Product(s) that are being conducted by FMI for the Product(s) and are ongoing as of the effective
date of termination; provided, however, that 
  

	(i)	both FMI and Roche in their reasonable judgment have concluded that completing any such clinical studies does not present an unreasonable risk to patient safety; 

 

	(ii)	neither Party shall have an obligation to recruit or enroll any additional patients after the effective date of termination; and 

  

	(iii)	FMI agrees to reimburse Roche for all of its development costs that incurred by or on behalf of Roche after the effective date of termination in completing such clinical studies as per subsection (a) above and
Roche agrees to reimburse FMI for all of its development costs that incurred by or on behalf of Roche after the effective date of termination in completing such clinical studies as per subsection (b) above. 

 

	17.3.4.2	Ancillary Agreements 

 Unless otherwise agreed by the Parties, the termination of this Agreement shall cause the
automatic termination of all ancillary agreements related hereto, including but not limited to supply or quality agreements, if any, but shall not cause the termination of the Related Agreements unless specifically stated in such Related Agreement.

  

	17.3.4.3	Limitations on Grant-Backs; Transfer Expenses 

 For purposes of clarity, irrespective of anything to the
contrary in this Agreement: 
  

	a)	All transfers and licenses from Roche to FMI or other obligations of Roche under Section 17.3 are solely with respect to Product(s). 

 

	b)	In connection with clinical trials, Roche may have collected human samples and related clinical information for additional limited research and development programs (“Samples”). Legal and contractual
restrictions may apply to such Samples, in particular as Samples may qualify as personal identifiable information. FMI acknowledges and accepts that notwithstanding anything herein, Roche shall not be obliged to transfer any such Samples to FMI.

  

	c)	Nothing in this Agreement shall be construed as granting FMI any license under the intellectual property of Roche or its Affiliates in existence as of the Effective Date. 

 

	d)	 Except with respect to termination by FMI for Roche’s breach pursuant to Section 17.2.2, FMI shall promptly reimburse Roche for all
reasonable out-of-pocket costs and expenses (including FTE charges based on Roche’s standard FTE rates) incurred by or on behalf of Roche for transfer of documents and materials as requested by FMI under this Article 17; however transfer
activities corresponding to the return of material remains, data, reports, 

  
 - 35 - 

	 	
records, documents, Regulatory Filings and Regulatory Approvals originally provided by FMI to Roche (“FMI-Originated Transfer Activities”) shall be at no expense to FMI. If FMI
desires Roche Transfer Activities other than FMI-Originated Transfer Activities, FMI shall make a payment to Roche of [...***...] (“Minimum Transfer Payment”). The Minimum Transfer Payment shall be non-refundable, but shall be
fully creditable against FMI’s reimbursement for the Roche Transfer Activities. Roche shall be under no obligation to provide Roche Transfer Activities (beyond the FMI-Originated Transfer Activities) prior to receipt of the Minimum Transfer
Payment. 

  

	17.3.5	Royalty and Payment Obligations 

 Termination of this Agreement by a Party, for any reason, shall not release
Roche from any obligation to pay royalties or make any payments to FMI that are payable for sales of Product prior to the effective date of termination. Termination of this Agreement by a Party, for any reason, will release Roche from any obligation
to pay royalties or make any payments to FMI that would otherwise become payable on or after the effective date of termination. 
  

	 	17.4	Survival 

 Article 1 (Definitions, to the extent necessary to interpret the Agreement), Article 10
(Taxes) Article 11 (Auditing), Article 12 (Intellectual Property, to the extent relating to intellectual property existing at the time of termination), Article 14 (Indemnification, to the extent relating to claims existing at the time or
termination), Article 16 (Obligation Not to Disclose Confidential Information), Section 17.3 (Consequences of Termination and Expiration, to the extent applicable), Section 17.4 (Survival), Section 19.1 (Governing Law) and
Section 19.3 (Arbitration) shall survive any expiration or termination of this Agreement for any reason. Notwithstanding the foregoing, any provision of this Agreement that is intended by its very nature to survive expiration or termination of
this Agreement shall also survive. 
  

	18.	Bankruptcy 

 All licenses (and to the extent applicable rights) granted under or pursuant to this
Agreement by FMI to Roche are, and shall otherwise be deemed to be, for purposes of Section 365(n) of Title 11, US Code (the “Bankruptcy Code”) licenses of rights to “intellectual property” as defined under
Section 101(60) of the Bankruptcy Code. Unless Roche elects to terminate this Agreement, the Parties agree that Roche, as a licensee or sublicensee of such rights under this Agreement, shall retain and may fully exercise all of its rights and
elections under the Bankruptcy Code, subject to the continued performance of its obligations under this Agreement. 
  

	19.	Miscellaneous 

  

	 	19.1	Governing Law 

 This Agreement shall be governed by and construed in accordance with the laws of New
York, US, without reference to its conflict of laws principles, and shall not be governed by the United Nations Convention of International Contracts on the Sale of Goods (the Vienna Convention). 

 

	 	19.2	Disputes 

 Unless otherwise set forth in this Agreement, in the event of any dispute in connection with
this Agreement, such dispute shall be referred to the respective executive officers of the Parties designated below or their designees, for good faith negotiations attempting to resolve the dispute. The designated executive officers are as follows:

  

			
	For FMI:		CEO
	For Roche:		Head of Roche Partnering or the CEO of the Roche Group in the case of Minimum Revenue Requirements.

  
 ***Confidential Treatment
Requested*** 
 - 36 - 

	 	19.3	Arbitration 

 Should the Parties fail to agree within [...***...] after such dispute has first
arisen, it shall be finally settled by arbitration in accordance with the Rules of American Arbitration Association (“AAA”) as in force at the time when initiating the arbitration. The tribunal shall consist of three arbitrators. The place
of arbitration shall be New York, New York, US. The language to be used shall be English. 
  

	19.3.1	Arbitrators 

 Each Party shall nominate one arbitrator. Should the claimant fail to appoint an arbitrator in the
request for arbitration within [...***...] of being requested to do so, or if the respondent should fail to appoint an arbitrator in its answer to the request for arbitration within [...***...] of being requested to do so, the other
Party shall request the AAA to make such appointment. 
 The arbitrators nominated by the Parties shall, within [...***...] from the appointment of
the arbitrator nominated in the answer to the request for arbitration, and after consultation with the Parties, agree and appoint a third arbitrator, who will act as a chairman of the Arbitral Tribunal. Should such procedure not result in an
appointment within the [...***...] time limit, either Party shall be free to request the AAA to appoint the third arbitrator. 
 Where there is more
than one claimant and/or more than one respondent, the multiple claimants or respondents shall jointly appoint one arbitrator. 
 Any Party-appointed
arbitrator or the third arbitrator resigns or ceases to be able to act, a replacement shall be appointed in accordance with the arrangements provided for in this clause. 

The language of the arbitration shall be English. Documents submitted in the arbitration (the originals of which are not in English) shall be submitted
together with an English translation. 
  

	19.3.2	Decisions; Timing of Decisions 

 The arbitrators shall render a written opinion setting forth findings of fact
and conclusions of law with the reason therefor stated, within no later than [...***...] from the date on which the arbitrators were appointed to the dispute. A transcript of the evidence adduced at the arbitration hearing shall be made and,
upon request, shall be made available to each Party. 
 The time periods set forth in the AAA Arbitration Rules shall be followed; provided however that the
arbitrators may modify such time periods as reasonably necessary to render a written opinion in accordance with this Section 19.3.2. 
 The Arbitrator
is empowered to award any remedy allowed by law, including money damages, prejudgment interest and attorneys’ fees, and to grant final, complete, interim, or interlocutory relief, including injunctive relief. 

  
 ***Confidential Treatment
Requested*** 
 - 37 - 

 This arbitration agreement does not preclude either Party seeking conservatory or interim measures from any court
of competent jurisdiction including, without limitation, the courts having jurisdiction by reason of either Party’s domicile. Conservatory or interim measures sought by either Party in any one or more jurisdictions shall not preclude the
Arbitral Tribunal granting conservatory or interim measures. Conservatory or interim measures sought by either Party before the Arbitral Tribunal shall not preclude any court of competent jurisdiction granting conservatory or interim measures. 

In the event that any issue shall arise which is not clearly provided for in this Section 19.3, the matter shall be resolved in accordance with the AAA
Arbitration Rules. 
 Any arbitration proceeding hereunder shall be confidential and the arbitrators shall issue appropriate protective orders to safeguard
each Party’s Confidential Information. Except as required by law, neither Party shall make (or instruct the arbitrators to make) any public announcement with respect to the proceedings or decision of the arbitrators without prior written
consent of the other Party. The existence of any dispute submitted to arbitration, and the award, shall be kept in confidence by the Parties and the arbitrators, except as required in connection with the enforcement of such award or as otherwise
required by Applicable Law. 
 Notwithstanding anything to the contrary in this Agreement, any and all issues regarding the scope, construction, validity
and/or enforceability of any Patent Rights shall be determined in a court of competent jurisdiction under the local patent laws of the jurisdictions having issued the Patent Rights in question. 

Notwithstanding anything to the contrary in this Agreement, any and all issues regarding a breach or alleged breach of a Party’s obligations under
Article 16 (Obligation Not to Disclose Confidential Information) shall be determined in a court of competent jurisdiction under the laws of New York, with express exclusion of its conflict of laws principles. 

 

	 	19.4	Assignment 

 Neither Party shall have the right to assign the present Agreement or any part thereof to
any Third Party other than Affiliates without the prior written approval of the other Party. 
  

	 	19.5	Compliance with Applicable Law 

 Each Party shall comply with Applicable Law in conducting activities and
carrying out responsibilities under this Agreement[, including the U.S. Foreign Corrupt Practices Act of 1977, as amended, (collectively hereinafter the “FCPA”) and anti-bribery laws in the countries in the Territory where Roche has
its principal place of business and where it conducts activities under this Agreement. 
  

	 	19.6	Debarment 

 Each Party represents and warrants that it has never been debarred under 21 U.S.C.
§335a, disqualified under 21 C.F.R. §312.70 or §812.119, sanctioned by a Federal Health Care Program (as defined in 42 U.S.C §1320 a-7b(f)), including without limitation the federal Medicare or a state Medicaid program, or
debarred, suspended, excluded or otherwise declared ineligible from any other similar Federal or state agency or program. In the event a Party receives notice of debarment, suspension, sanction, exclusion, ineligibility or disqualification under the
above-referenced statutes, such Party shall [...***...]. 

  
 ***Confidential Treatment
Requested*** 
 - 38 - 

 Each Party agrees that, to the best of its knowledge, none of its employees or agents conducting activities on
its behalf under the Agreement is currently or will be during the term of this Agreement, debarred under 21 U.S.C. §335a, disqualified under 21 C.F.R. §312.70 or §812.119, sanctioned by a Federal Health Care Program (as defined in 42
U.S.C §1320 a-7b(f)), including without limitation the federal Medicare or a state Medicaid program, or debarred, suspended, excluded or otherwise declared ineligible from any other similar Federal or state agency or program. In the event a
Party learns that any such employee or agent becomes so debarred, sanctioned, suspended, excluded or declared ineligible or is the subject of proceedings that may result in such debarment, sanction, suspension, exclusion or ineligibility, it will
promptly so notify the other Party and will no longer allow such employee or agent to conduct activities under this Agreement. 
  

	 	19.7	Independent Contractor 

 No employee or representative of either Party shall have any authority to bind
or obligate the other Party to this Agreement for any sum or in any manner whatsoever or to create or impose any contractual or other liability on the other Party without said Party’s prior written approval. For all purposes, and not-
withstanding any other provision of this Agreement to the contrary, FMI legal relationship to Roche under this Agreement shall be that of independent contractor. 
  

	 	19.8	Unenforceable Provisions and Severability 

 If any of the provisions of this Agreement are held to be
void or unenforceable, then such void or unenforceable provisions shall be replaced by valid and enforceable provisions that will achieve as far as possible the economic business intentions of the Parties. However the remainder of this Agreement
will remain in full force and effect, provided that the material interests of the Parties are not affected, i.e. the Parties would presumably have concluded this Agreement without the unenforceable provisions. 

 

	 	19.9	Waiver 

 The failure by either Party to require strict performance and/or observance of any obligation,
term, provision or condition under this Agreement will neither constitute a waiver thereof nor affect in any way the right of the respective Party to require such performance and/or observance. The waiver by either Party of a breach of any
obligation, term, provision or condition hereunder shall not constitute a waiver of any subsequent breach thereof or of any other obligation, term, provision or condition. 
  

	 	19.10	Appendices 

 All Appendices to this Agreement shall form an integral part to this Agreement. 

 

	 	19.11	Entire Understanding 

 This Agreement contains the entire understanding between the Parties hereto with
respect to the within subject matter and supersedes any and all prior agreements, understandings and arrangements, whether written or oral. 

  
 - 39 - 

	 	19.12	Amendments 

 No amendments of the terms and conditions of this Agreement shall be binding upon either
Party hereto unless in writing and signed by both Parties. 
  

	 	19.13	Invoices 

 All invoices that are required or permitted hereunder shall be in writing and sent by FMI to
Roche at the following address or other address as Roche may later provide: 
 F. Hoffmann-La Roche Ltd 

Kreditorenbuchhaltung 
 4070
Basel 
 Switzerland 
  

	 	19.14	Notice 

 All notices that are required or permitted hereunder shall be in writing and sufficient if
delivered personally, sent by facsimile (and promptly confirmed by personal delivery, registered or certified mail or overnight courier), sent by nationally recognized overnight courier or sent by registered or certified mail, postage prepaid,
return receipt requested, addressed as follows: 
  

			
	if to FMI, to:		 Foundation Medicine, Inc.
 150 Second Street

Cambridge, MA 02141
 Attn: Legal Department

Facsimile No.: (617) 418-2201

		
	if to Roche, to:		 F. Hoffmann-La Roche Ltd
 Grenzacherstrasse
124
 4070 Basel
 Switzerland

Attn: Legal Department
 Facsimile No.: +41 61 688 13
96

 or to such other address as the Party to whom notice is to be given may have furnished to the other Party in writing in
accordance herewith. The effective date of any notice shall be: (a) the date of the addressee’s receipt, if delivered personally, by courier, or by registered or certified mail; or (b) the date of receipt if received by 5:00 p.m.
local time on a business day or, if not, the first business day after receipt, if sent by facsimile. 
  

	 	19.15	Subcontractors 

 Subject to Section 2.1.2, either Party may perform any of its obligations under this
Agreement, including under the Tactical Plans and Post Approval Plans, through one or more subcontractors or consultants; provided that (i) such Party remains responsible for the work allocated to, and payment to, such subcontractors and
consultants to the same extent it would if it had done such work itself, and such Party shall be liable for any act or omission of such subcontractor and consultant that is a breach of any of such Party’s obligations under this Agreement as
though the same were a breach by such Party, and the other Party shall have the right to proceed directly 

  
 - 40 - 

 
against such Party without any obligation to first proceed against such subcontractor or consultant; (ii) the subcontractor or consultant undertakes in writing commercially reasonable
obligations of confidentiality and non-use regarding Confidential Information, that are substantially the same as those undertaken by the Parties with respect to Confidential Information pursuant to Article 16 hereof; and (iii) the
subcontractor or consultant undertakes in writing to assign or exclusively license back (with the right to sublicense) all intellectual property with respect to Product developed in the course of performing any such work under the Tactical Plans and
Post Approval Plans to the subcontracting Party. Notwithstanding the above, if a the work to be done by the subcontractor or consultant is material to the performance of a Party under this Agreement, then the Party engaging such subcontractor or
consultant shall seek the consent of the other Party, which consent shall not be unreasonably withheld. 
  

	 	19.16	Force Majeure 

 Both Parties shall be excused from the performance of their obligations under this
Agreement to the extent that such performance is prevented or delayed by force majeure and the nonperforming Party promptly provides notice of the prevention to the other Party. Such excuse shall be continued so long as the condition constituting
force majeure continues and the nonperforming Party takes reasonable efforts to remove the condition. For purposes of this Agreement, force majeure means conditions beyond the reasonable control of the Parties, including an act of God, war, civil
commotion, terrorist act, labor strike or lock-out, epidemic, failure or default of public utilities or common carriers, destruction of production facilities or materials by fire, earthquake, storm or like catastrophe, and failure of plant or
machinery (provided that such failure could not have been prevented by the exercise of skill, diligence, and prudence that would be reasonably and ordinarily expected from a skilled and experienced person engaged in the same type of undertaking
under the same or similar circumstances). Notwithstanding the foregoing, a Party shall not be excused from making payments owed hereunder because of a force majeure affecting such Party. 

[Signature Page Follows] 

  
 - 41 - 

 IN WITNESS WHEREOF, the Parties have entered into this Agreement as of the Effective Date. 

 

			
	Foundation Medicine, Inc.
	
	 /s/ Stefan J. Kafka

		
	Name:		Steven J. Kafka
		
	Title:		Chief Operating Officer

  

									
	F. Hoffmann-La Roche Ltd						
			
	 /s/ Jason Coloma
				 /s/ Stefan Arnold

					
	Name:		Jason Coloma 				Name:		Stefan Arnold
					
	Title:		Global Head of Venture & Innovation, Roche Partnering				Title:		Head Legal Pharma

  

 Appendix 1.19 

Existing Third Party Rights 

[...***...]. 

  
 ***Confidential Treatment
Requested*** 

 Appendix 2.3 

Product Specifications 

[...***...] [...***...] [...***...] [...***...] [...***...] [...***...] [...***...] [...***...] 

[...***...] [...***...] [...***...] [...***...] [...***...] [...***...] [...***...] [...***...] 

[...***...] [...***...] [...***...] [...***...] [...***...] [...***...] [...***...] [...***...] 

[...***...] [...***...] [...***...] [...***...] [...***...] [...***...] [...***...] [...***...] 

[...***...] [...***...] [...***...] [...***...] [...***...] [...***...] [...***...] [...***...] 

[...***...] [...***...] [...***...] [...***...] [...***...] [...***...] [...***...] [...***...] 

[...***...] [...***...] [...***...] [...***...] [...***...] [...***...] [...***...] [...***...] 

[...***...] [...***...] [...***...] [...***...] [...***...] [...***...] [...***...] [...***...] 

[...***...] [...***...] [...***...] [...***...] [...***...] [...***...] [...***...] [...***...] 

[...***...] [...***...] [...***...] [...***...] [...***...] [...***...] [...***...] [...***...] 

[...***...] [...***...] [...***...] [...***...] [...***...] [...***...] [...***...] [...***...] 

[...***...] [...***...] [...***...] [...***...] [...***...] [...***...] [...***...] [...***...] 

[...***...] [...***...] [...***...] [...***...] [...***...] [...***...] [...***...] [...***...] 

[...***...] [...***...] [...***...] [...***...] [...***...] [...***...] [...***...] [...***...] 

[...***...] [...***...] [...***...] [...***...] [...***...] [...***...] [...***...] [...***...] 

[...***...] [...***...] [...***...] [...***...] [...***...] [...***...] [...***...] [...***...] 

[...***...] [...***...] [...***...] [...***...] [...***...] [...***...] [...***...] [...***...] 

[...***...] [...***...] [...***...] [...***...] [...***...] [...***...] [...***...] [...***...] 

[...***...] [...***...] [...***...] [...***...] [...***...] [...***...] [...***...] [...***...] 

[...***...] [...***...] [...***...] [...***...] [...***...] [...***...] [...***...] [...***...] 

[...***...] [...***...] [...***...] [...***...] [...***...] [...***...] [...***...] [...***...] 

[...***...] [...***...] [...***...] [...***...] [...***...] [...***...] [...***...] [...***...] 

***Confidential Treatment Requested*** 

 [...***...] [...***...] [...***...] [...***...] [...***...] [...***...] [...***...] [...***...]

 [...***...] [...***...] [...***...] [...***...] [...***...] [...***...] [...***...] [...***...] 

[...***...] [...***...] [...***...] [...***...] [...***...] [...***...] [...***...] [...***...] 

[...***...] [...***...] [...***...] [...***...] [...***...] [...***...] [...***...] [...***...] 

[...***...] [...***...] [...***...] [...***...] [...***...] [...***...] [...***...] [...***...] 

[...***...] [...***...] [...***...] [...***...] [...***...] [...***...] [...***...] [...***...] 

[...***...] [...***...] [...***...] [...***...] [...***...] [...***...] [...***...] [...***...] 

[...***...] [...***...] [...***...] [...***...] [...***...] [...***...] [...***...] [...***...] 

[...***...] [...***...] [...***...] [...***...] [...***...] [...***...] [...***...] [...***...] 

[...***...] [...***...] [...***...] [...***...] [...***...] [...***...] [...***...] [...***...] 

[...***...] [...***...] [...***...] [...***...] [...***...] [...***...] [...***...] [...***...] 

[...***...] [...***...] [...***...] [...***...] [...***...] [...***...] [...***...] [...***...] 

[...***...] [...***...] [...***...] [...***...] [...***...] [...***...] [...***...] [...***...] 

[...***...] [...***...] [...***...] [...***...] [...***...] [...***...] [...***...] [...***...] 

[...***...] [...***...] [...***...] [...***...] [...***...] [...***...] [...***...] [...***...] 

[...***...] [...***...] [...***...] [...***...] [...***...] [...***...] [...***...] [...***...] 

[...***...] [...***...] [...***...] [...***...] [...***...] [...***...] [...***...] [...***...] 

[...***...] [...***...] [...***...] [...***...] [...***...] [...***...] [...***...] [...***...] 

[...***...] [...***...] [...***...] [...***...] [...***...] [...***...] [...***...] [...***...] 

[...***...] [...***...] [...***...] [...***...] [...***...] [...***...] [...***...] [...***...] 

[...***...] [...***...] [...***...] [...***...] [...***...] [...***...] [...***...] [...***...] 

[...***...] [...***...] [...***...] [...***...] [...***...] [...***...] [...***...] [...***...] 

***Confidential Treatment Requested*** 

  
 A-2 

 [...***...] [...***...] [...***...] [...***...] [...***...] [...***...] [...***...] [...***...]

 [...***...] [...***...] [...***...] [...***...] [...***...] [...***...] [...***...] [...***...] 

[...***...] [...***...] [...***...] [...***...] [...***...] [...***...] [...***...] [...***...] 

[...***...] [...***...] [...***...] [...***...] [...***...] [...***...] [...***...] [...***...] 

[...***...] [...***...] [...***...] [...***...] [...***...] [...***...] [...***...] [...***...] 

[...***...] [...***...] [...***...] [...***...] [...***...] [...***...] [...***...] [...***...] 

[...***...] [...***...] [...***...] [...***...] [...***...] [...***...] [...***...] [...***...] 

[...***...] [...***...] [...***...] [...***...] [...***...] [...***...] [...***...] [...***...] 

[...***...] [...***...] [...***...] [...***...] [...***...] [...***...] [...***...] [...***...] 

[...***...] [...***...] [...***...] [...***...] [...***...] [...***...] [...***...] [...***...] 

[...***...] [...***...] [...***...] [...***...] [...***...] [...***...] [...***...] [...***...] 

[...***...] [...***...] [...***...] [...***...] [...***...] [...***...] [...***...] [...***...] 

[...***...] [...***...] [...***...] [...***...] [...***...] [...***...] [...***...] [...***...] 

[...***...] [...***...] [...***...] [...***...] [...***...] [...***...] [...***...] [...***...] 

[...***...] [...***...] [...***...] [...***...] [...***...] [...***...] [...***...] [...***...] 

[...***...] [...***...] [...***...] [...***...] [...***...] [...***...] [...***...] [...***...] 

[...***...] [...***...] [...***...] [...***...] [...***...] [...***...] [...***...] [...***...] 

[...***...] [...***...] [...***...] [...***...] [...***...] [...***...] [...***...] [...***...] 

[...***...] [...***...] [...***...] [...***...] [...***...] [...***...] [...***...] [...***...] 

[...***...] [...***...] [...***...] [...***...] [...***...] [...***...] [...***...] [...***...] 

[...***...] [...***...] [...***...] [...***...] [...***...] [...***...] [...***...] [...***...] 

[...***...] [...***...] [...***...] [...***...] [...***...] [...***...] [...***...] [...***...] 

***Confidential Treatment Requested*** 

  
 A-3 

 [...***...] [...***...] [...***...] [...***...] [...***...] [...***...] [...***...] [...***...]

 [...***...] [...***...] [...***...] [...***...] [...***...] [...***...] [...***...] [...***...] 

[...***...] [...***...] [...***...] [...***...] [...***...] [...***...] [...***...] [...***...] 

[...***...] [...***...] [...***...] [...***...] [...***...] [...***...] [...***...] [...***...] 

[...***...] [...***...] [...***...] [...***...] [...***...] [...***...] [...***...] [...***...] 

[...***...] [...***...] [...***...] [...***...] [...***...] [...***...] [...***...] [...***...] 

[...***...] [...***...] [...***...] [...***...] [...***...] [...***...] [...***...] [...***...] 

[...***...] [...***...] [...***...] [...***...] [...***...] [...***...] [...***...] [...***...] 

[...***...] [...***...] [...***...] [...***...] [...***...] [...***...] [...***...] [...***...] 

[...***...] [...***...] [...***...] [...***...] [...***...] [...***...] [...***...] [...***...] 

[...***...] [...***...] [...***...] [...***...] [...***...] [...***...] [...***...] [...***...] 

[...***...] [...***...] [...***...] [...***...] [...***...] [...***...] [...***...] [...***...] 

[...***...] [...***...] [...***...] [...***...] [...***...] [...***...] [...***...] [...***...] 

[...***...] [...***...] [...***...] [...***...] [...***...] [...***...] [...***...] [...***...] 

[...***...] [...***...] [...***...] [...***...] [...***...] [...***...] [...***...] [...***...] 

[...***...] [...***...] [...***...] [...***...] [...***...] [...***...] [...***...] [...***...] 

[...***...] [...***...] [...***...] [...***...] [...***...] [...***...] [...***...] [...***...] 

[...***...] [...***...] [...***...] [...***...] [...***...] [...***...] [...***...] [...***...] 

[...***...] [...***...] [...***...] [...***...] [...***...] [...***...] [...***...] [...***...] 

[...***...] [...***...] [...***...] [...***...] [...***...] [...***...] [...***...] [...***...] 

[...***...] [...***...] [...***...] [...***...] [...***...] [...***...] [...***...] [...***...] 

[...***...] [...***...] [...***...] [...***...] [...***...] [...***...] [...***...] [...***...] 

***Confidential Treatment Requested*** 

  
 A-4 

 [...***...] [...***...] [...***...] [...***...] [...***...] [...***...] [...***...] [...***...]

 [...***...] [...***...] [...***...] [...***...] [...***...] [...***...] [...***...] [...***...] 

[...***...] [...***...] [...***...] [...***...] [...***...] [...***...] [...***...] [...***...] 

[...***...] [...***...] [...***...] [...***...] [...***...] [...***...] [...***...] [...***...] 

[...***...] [...***...] [...***...] [...***...] [...***...] [...***...] [...***...] [...***...] 

[...***...] [...***...] [...***...] [...***...] [...***...] [...***...] [...***...] [...***...] 

[...***...] [...***...] [...***...] [...***...] [...***...] [...***...] [...***...] [...***...] 

[...***...] [...***...] [...***...] [...***...] [...***...] [...***...] [...***...] [...***...] 

[...***...] [...***...] [...***...] [...***...] [...***...] [...***...] [...***...] [...***...] 

[...***...] [...***...] [...***...] [...***...] [...***...] [...***...] [...***...] [...***...] 

[...***...] [...***...] [...***...] [...***...] [...***...] [...***...] [...***...] [...***...] 

[...***...] [...***...] [...***...] [...***...] [...***...] [...***...] [...***...] [...***...] 

[...***...] [...***...] [...***...] [...***...] [...***...] [...***...] [...***...] [...***...] 

[...***...] [...***...] [...***...] [...***...] [...***...] [...***...] [...***...] [...***...] 

[...***...] [...***...] [...***...] [...***...] [...***...] [...***...] [...***...] [...***...] 

[...***...] [...***...] [...***...] [...***...] [...***...] [...***...] [...***...] [...***...] 

[...***...] [...***...] [...***...] [...***...] [...***...] [...***...] [...***...] [...***...] 

[...***...] [...***...] [...***...] [...***...] [...***...] [...***...] [...***...] [...***...] 

[...***...] [...***...] [...***...] [...***...] [...***...] [...***...] [...***...] [...***...] 

[...***...] [...***...] [...***...] [...***...] [...***...] [...***...] [...***...] [...***...] 

[...***...] [...***...] [...***...] [...***...] [...***...] [...***...] [...***...] [...***...] 

[...***...] [...***...] [...***...] [...***...] [...***...] [...***...] [...***...] [...***...] 

***Confidential Treatment Requested*** 

  
 A-5 

 [...***...] [...***...] [...***...] [...***...] [...***...] [...***...] [...***...] [...***...]

 [...***...] [...***...] [...***...] [...***...] [...***...] [...***...] [...***...] [...***...] 

[...***...] [...***...] [...***...] [...***...] [...***...] [...***...] [...***...] [...***...] 

[...***...] [...***...] [...***...] [...***...] [...***...] [...***...] [...***...] [...***...] 

[...***...] [...***...] [...***...] [...***...] [...***...] [...***...] [...***...] [...***...] 

[...***...] [...***...] [...***...] [...***...] [...***...] [...***...] [...***...] [...***...] 

[...***...] [...***...] [...***...] [...***...] [...***...] [...***...] [...***...] [...***...] 

[...***...] [...***...] [...***...] [...***...] [...***...] [...***...] [...***...] [...***...] 

[...***...] [...***...] [...***...] [...***...] [...***...] [...***...] [...***...] [...***...] 

[...***...] [...***...] [...***...] [...***...] [...***...] [...***...] [...***...] [...***...] 

[...***...] [...***...] [...***...] [...***...] [...***...] [...***...] [...***...] [...***...] 

[...***...] [...***...] [...***...] [...***...] [...***...] [...***...] [...***...] [...***...] 

[...***...] [...***...] [...***...] [...***...] [...***...] [...***...] [...***...] [...***...] 

[...***...] [...***...] [...***...] [...***...] [...***...] [...***...] [...***...] [...***...] 

[...***...] [...***...] [...***...] [...***...] [...***...] [...***...] [...***...] [...***...] 

[...***...] [...***...] [...***...] [...***...] [...***...] [...***...] [...***...] [...***...] 

[...***...] [...***...] [...***...] [...***...] [...***...] [...***...] [...***...] [...***...] 

[...***...] [...***...] [...***...] [...***...] [...***...] [...***...] [...***...] [...***...] 

[...***...] [...***...] [...***...] [...***...] [...***...] [...***...] [...***...] [...***...] 

[...***...] [...***...] [...***...] [...***...] [...***...] [...***...] [...***...] [...***...] 

[...***...] [...***...] [...***...] [...***...] [...***...] [...***...] [...***...] [...***...] 

[...***...] [...***...] [...***...] [...***...] [...***...] [...***...] [...***...] [...***...] 

***Confidential Treatment Requested*** 

  
 A-6 

 [...***...] [...***...] [...***...] [...***...] [...***...] [...***...] [...***...] [...***...]

 [...***...] [...***...] [...***...] [...***...] [...***...] [...***...] [...***...] [...***...] 

[...***...] [...***...] [...***...] [...***...] [...***...] [...***...] [...***...] [...***...] 

[...***...] [...***...] [...***...] [...***...] [...***...] [...***...] [...***...] [...***...] 

[...***...] [...***...] [...***...] [...***...] [...***...] [...***...] [...***...] [...***...] 

[...***...] [...***...] [...***...] [...***...] [...***...] [...***...] [...***...] [...***...] 

[...***...] [...***...] [...***...] [...***...] [...***...] [...***...] [...***...] [...***...] 

[...***...] [...***...] [...***...] [...***...] [...***...] [...***...] [...***...] [...***...] 

[...***...] [...***...] [...***...] [...***...] [...***...] [...***...] [...***...] [...***...] 

[...***...] [...***...] [...***...] [...***...] [...***...] [...***...] [...***...] [...***...] 

[...***...] [...***...] [...***...] [...***...] [...***...] [...***...] [...***...] [...***...] 

[...***...] [...***...] [...***...] [...***...] [...***...] [...***...] [...***...] [...***...] 

[...***...] [...***...] [...***...] [...***...] [...***...] [...***...] [...***...] [...***...] 

[...***...] [...***...] [...***...] [...***...] [...***...] [...***...] [...***...] [...***...] 

[...***...] [...***...] [...***...] [...***...] [...***...] [...***...] [...***...] [...***...] 

[...***...] [...***...] [...***...] [...***...] [...***...] [...***...] [...***...] [...***...] 

[...***...] [...***...] [...***...] [...***...] [...***...] [...***...] [...***...] [...***...] 

[...***...] [...***...] [...***...] [...***...] [...***...] [...***...] [...***...] [...***...] 

[...***...] [...***...] [...***...] [...***...] [...***...] [...***...] [...***...] [...***...] 

[...***...] [...***...] [...***...] [...***...] [...***...] [...***...] [...***...] [...***...] 

[...***...] [...***...] [...***...] [...***...] [...***...] [...***...] [...***...] [...***...] 

[...***...] [...***...] [...***...] [...***...] [...***...] [...***...] [...***...] [...***...] 

***Confidential Treatment Requested*** 

  
 A-7 

 [...***...] [...***...] [...***...] [...***...] [...***...] [...***...] [...***...] [...***...]

 [...***...] [...***...] [...***...] [...***...] [...***...] [...***...] [...***...] [...***...] 

[...***...] [...***...] [...***...] [...***...] [...***...] [...***...] [...***...] [...***...] 

[...***...] [...***...] [...***...] [...***...] [...***...] [...***...] [...***...] [...***...] 

[...***...] [...***...] [...***...] [...***...] [...***...] [...***...] [...***...] [...***...] 

[...***...] [...***...] [...***...] [...***...] [...***...] [...***...] [...***...] [...***...] 

[...***...] [...***...] [...***...] [...***...] [...***...] [...***...] [...***...] [...***...] 

[...***...] [...***...] [...***...] [...***...] [...***...] [...***...] [...***...] [...***...] 

[...***...] [...***...] [...***...] [...***...] [...***...] [...***...] [...***...] [...***...] 

[...***...] [...***...] [...***...] [...***...] [...***...] [...***...] [...***...] [...***...] 

[...***...] [...***...] [...***...] [...***...] [...***...] [...***...] [...***...] [...***...] 

[...***...] [...***...] [...***...] [...***...] [...***...] [...***...] [...***...] [...***...] 

[...***...] [...***...] [...***...] [...***...] [...***...] [...***...] [...***...] [...***...] 

[...***...] [...***...] [...***...] [...***...] [...***...] [...***...] [...***...] [...***...] 

[...***...] [...***...] [...***...] [...***...] [...***...] [...***...] [...***...] [...***...] 

[...***...] [...***...] [...***...] [...***...] [...***...] [...***...] [...***...] [...***...] 

[...***...] [...***...] [...***...] [...***...] [...***...] [...***...] [...***...] [...***...] 

[...***...] [...***...] [...***...] [...***...] [...***...] [...***...] [...***...] [...***...] 

[...***...] [...***...] [...***...] [...***...] [...***...] [...***...] [...***...] [...***...] 

[...***...] [...***...] [...***...] [...***...] [...***...] [...***...] [...***...] [...***...] 

[...***...] [...***...] [...***...] [...***...] [...***...] [...***...] [...***...] [...***...] 

[...***...] [...***...] [...***...] [...***...] [...***...] [...***...] [...***...] [...***...] 

***Confidential Treatment Requested*** 

  
 A-8EX-10.4

 Exhibit 10.4 

EXECUTION COPY 
 ***Text Omitted and Filed
Separately with the Securities and Exchange Commission 
 Confidential Treatment Requested Under 

17 C.F.R. Sections 200.80(b)(4) and 240.24b-2 

US Education Collaboration Agreement 

This Agreement is entered into with effect as of the Effective Date (as defined below) 

by and between 
 Genentech, Inc. 

with an office and place of business at 1 DNA Way, South San Francisco, California 94080 (“Genentech”) 

and 
 Foundation Medicine, Inc. 

with an office and place of business at 150 Second Street, Cambridge, Massachusetts 02141 (“FMI”) on the other hand. 

  

 Table of Contents 

 

									
	1.	  	Definitions	  	 	5	  
		  	1.1	  	Affiliate	  	 	5	  
		  	1.2	  	Agreement	  	 	5	  
		  	1.3	  	Agreement Term	  	 	5	  
		  	1.4	  	Applicable Law	  	 	5	  
		  	1.5	  	Business Day	  	 	5	  
		  	1.6	  	Calendar Quarter	  	 	5	  
		  	1.7	  	Calendar Year	  	 	5	  
		  	1.8	  	CGP	  	 	5	  
		  	1.9	  	Commercially Reasonable Efforts	  	 	5	  
		  	1.10	  	Confidential Information	  	 	6	  
		  	1.11	  	Control	  	 	6	  
		  	1.12	  	Educational Materials	  	 	6	  
		  	1.13	  	Education Support Program	  	 	6	  
		  	1.14	  	Education Support Working Group	  	 	6	  
		  	1.15	  	Effective Date	  	 	6	  
		  	1.16	  	FDCA	  	 	6	  
		  	1.17	  	FTE	  	 	6	  
		  	1.18	  	FTE Rate	  	 	6	  
		  	1.19	  	Government Agency	  	 	7	  
		  	1.20	  	Healthcare Laws	  	 	7	  
		  	1.21	  	Insolvency Event	  	 	7	  
		  	1.22	  	JOC	  	 	7	  
		  	1.23	  	Know-How	  	 	7	  
		  	1.24	  	Party	  	 	7	  
		  	1.25	  	PREP Team	  	 	7	  
		  	1.26	  	Regulatory Authority	  	 	7	  
		  	1.27	  	Roche Group	  	 	7	  
		  	1.28	  	Tactical Plan	  	 	8	  
		  	1.29	  	Third Party	  	 	8	  
		  	1.30	  	US	  	 	8	  
		  	1.31	  	US$	  	 	8	  
		  	1.32	  	Additional Definitions	  	 	8	  
	2.	  	US Education Collaboration	  	 	9	  
		  	2.1	  	Education Support Program	  	 	9	  
		  	2.2	  	Governance	  	 	13	  
	3.	  	Costs	  	 	15	  
		  	3.1	  	[...***...]	  	 	15	  
		  	3.2	  	Other Costs	  	 	15	  
		  	3.3	  	Disclosure of Payments	  	 	15	  
	4.	  	Payments	  	 	15	  
		  	4.1	  	Timing of Payments	  	 	15	  
		  	4.2	  	Late Payments	  	 	15	  
		  	4.3	  	Method of Payments	  	 	15	  

  
 ***Confidential Treatment
Requested*** 
 - 2 - 

									
	5.		Co-Promote Option		 	16	  
	6.		Intellectual Property		 	16	  
			6.1		Ownership and Use		 	16	  
			6.2		No Implied Licenses		 	17	  
	7.		Representations and Warranties		 	17	  
			7.1		Mutual Representations and Warranties		 	17	  
			7.2		No Other Representations		 	18	  
	8.		Liability		 	18	  
	9.		Term and Termination		 	18	  
			9.1		Commencement and Term		 	18	  
			9.2		Termination		 	18	  
			9.3		Consequences of Termination		 	19	  
			9.4		Survival		 	19	  
	10.		Matters Governed by the Collaboration Agreement		 	20	  
			10.1		Auditing		 	20	  
			10.2		Indemnification		 	20	  
			10.3		Confidentiality		 	20	  
			10.4		Assignment		 	20	  
			10.5		Debarment and Exclusion		 	20	  
	11.		Miscellaneous		 	20	  
			11.1		Governing Law		 	20	  
			11.2		Disputes		 	20	  
			11.3		Independent Contractor		 	21	  
			11.4		Unenforceable Provisions and Severability		 	21	  
			11.5		Waiver		 	21	  
			11.6		Appendices		 	21	  
			11.7		Entire Understanding		 	21	  
			11.8		Amendments		 	21	  
			11.9		Invoices		 	21	  
			11.10		Notice		 	22	  

  
 - 3 - 

 US Education Collaboration Agreement 

WHEREAS, FMI has or is developing platforms for use in genomic testing, and has expertise in comprehensive genomic profiling and next generation sequencing
technology; and 
 WHEREAS, Genentech has expertise in the research, development, manufacture and commercialization of pharmaceutical and diagnostic
products; and 
 WHEREAS, Genentech wishes to extend its leadership position in education in personalized healthcare and genetic testing by adding
comprehensive genomic profiling to its educational offerings for pathologists and laboratories; and 
 WHEREAS, Genentech is able to undertake such
educational efforts at this time based, in part, on the financial contribution that FMI is providing hereunder; and 
 WHEREAS, Genentech and FMI want to
work together in the United States to educate relevant persons on comprehensive genomic profiling technology; and 
 WHEREAS, FMI and
Genentech’s Affiliates F. Hoffmann-La Roche Ltd (“Roche Basel”) and Hoffmann-La Roche Inc. (“Roche US”; Roche Basel and Roche US together referred to as
“Roche”) are engaged in a series of transactions, including (a) agreements under which Roche will acquire a majority ownership of FMI, (b) an agreement under which Roche will be responsible for the commercialization of
certain FMI diagnostic products outside of the United States (“Ex-US Commercialization Agreement”), (c) a term sheet under which FMI and Roche will potentially collaborate on the
development of in vitro diagnostic kits, and (d) an agreement under which FMI and Roche will collaborate on the development of platforms for use in molecular information, immunotherapy, circulating tumor DNA, and
companion diagnostics (“Collaboration Agreement”), the foregoing agreements and term sheet referred to collectively as the “Related Agreements”; and  

WHEREAS, FMI and Genentech intend that the governance structure under the Collaboration Agreement will apply to certain matters under this Agreement. 

  
 - 4 - 

 NOW, THEREFORE, in consideration of the mutual covenants and promises contained in this Agreement and other good
and valuable consideration, the receipt and sufficiency of which are hereby acknowledged, the Parties hereto, intending to be legally bound, do hereby agree as follows: 
  

	1.	Definitions 

 As used in this Agreement, the following terms, whether used in the singular or plural,
shall have the following meanings: 
  

	1.1	Affiliate 

 The term “Affiliate” shall have the meaning set forth in the Collaboration
Agreement, provided that references to Roche shall be replaced by references to Genentech. 
  

	1.2	Agreement 

 The term “Agreement” shall mean this document including any and all appendices and
amendments to it as may be added and/or amended from time to time in accordance with the provisions of this Agreement. 
  

	1.3	Agreement Term 

 The term “Agreement Term” shall mean the period of time commencing on the
Effective Date and expiring five (5) years thereafter, unless such period is extended by the written agreement of the Parties. 
  

	1.4	Applicable Law 

 The term “Applicable Law” shall have the meaning set forth in the
Collaboration Agreement. 
  

	1.5	Business Day 

 The term “Business Day” shall mean 9:00 am to 5:00 pm local time on a
day other than a Saturday, Sunday or bank or other public or federal holiday in California or Massachusetts. 
  

	1.6	Calendar Quarter 

 The term “Calendar Quarter” shall mean each period of three
(3) consecutive calendar months, ending March 31, June 30, September 30 and December 31. 
  

	1.7	Calendar Year 

 The term “Calendar Year” shall mean the period of time beginning on
January 1 and ending December 31, except for the first Calendar Year, which shall begin on the Effective Date and end on December 31. 
  

	1.8	CGP 

 The term “CGP” shall mean comprehensive genomic profiling, which may include using next
generation sequencing technology. 
  

	1.9	Commercially Reasonable Efforts 

 The term “Commercially Reasonable Efforts” shall mean efforts
and resources comparable with the efforts and resources Genentech or FMI, as applicable, devotes to a similar obligation in connection with projects of a similar nature. 

  
 - 5 - 

	1.10	Confidential Information 

 The term “Confidential Information” shall have the meaning set forth
in the Collaboration Agreement. The terms of this Agreement shall be considered Confidential Information of the Parties. 
  

	1.11	Control 

 The term “Control” shall mean (as an adjective or as a verb including conjugations
and variations such as “Controls,” “Controlled” or “Controlling”) (a) with respect to Know-How and intellectual property rights, the possession by a Party of the ability to grant a license or sublicense of such
Know-How and intellectual property rights without violating the terms of any agreement or arrangement between such Party and any other party and (b) with respect to proprietary materials, the possession by a Party of the ability to supply such
proprietary materials to the other Party as provided herein without violating the terms of any agreement or arrangement between such Party and any other party. 
  

	1.12	Educational Materials 

 The term “Educational Materials” shall mean materials intended to
educate healthcare professionals about CGP, which Genentech shall develop for its own use. 
  

	1.13	Education Support Program 

 The term “Education Support Program” shall mean a program under
which (a) FMI shall train PREP Team members about CGP; (b) Genentech shall develop the Educational Materials; and (c) PREP Team members, and other representatives of Genentech, shall conduct Educational Activities and
perform other activities related to CGP education directed to healthcare professionals. 
  

	1.14	Education Support Working Group 

 The term “Education Support Working Group” or
“ESWG” shall mean the group of persons from both Parties who will handle the day-to-day activities associated with the Education Support Program. 
  

	1.15	Effective Date 

 The term “Effective Date” shall mean the date on which the Collaboration
Agreement becomes effective. 
  

	1.16	FDCA 

 The term “FDCA” shall mean the Food, Drug and Cosmetics Act. 

 

	1.17	FTE 

 The term “FTE” shall mean a full-time equivalent
person-year, based upon a total of no less than one thousand eight hundred (1,800) working hours per year. In no circumstance can the work of any given person exceed one (1) FTE. 

 

	1.18	FTE Rate 

 The term “FTE Rate” shall mean [...***...] per FTE on a fully burdened
cost basis, which amount shall be subject to increase using the methodology for increasing the FTE Rate under the Collaboration Agreement mutatis mutandis. 

  
 ***Confidential Treatment
Requested*** 
 - 6 - 

	1.19	Government Agency 

 The term “Government Agency” shall mean any department or agency of the US
or any US state government with the authority to interpret, regulate under or enforce any Healthcare Laws, which may include a US or US state Regulatory Authority. 
  

	1.20	Healthcare Laws 

 The term “Healthcare Laws” shall mean (a) criminal and civil federal and
state fraud and laws including, without limitation, the Civil False Claims Act (31 USC §§ 3729-3733), the Criminal False Claims Act (18 USC § 287), the Anti-Kickback Statute (42 USC § 1320A-7b(b)) and associated regulatory safe harbors (42 CFR § 1001.952), the Physician Self-Referral Law
(42 USC § 1395nn), the Criminal Health Care Fraud (18 USC § 1347), the Exclusion Statute (42 USC Section 1320a-7) and the Civil Monetary Penalties Law (42 USC § 1320a-7a); and any US state law equivalents of any of the foregoing; (b) criminal and civil federal and state drug and medical device marketing, advertising and promotional laws, including without
limitation the FDCA, and any US state law equivalents thereof; and (c) criminal and civil federal and state consumer protection laws including without limitation Federal Trade Commission Act (15 U.S.C. §§ 41-58); and any US state law
equivalents thereof. 
  

	1.21	Insolvency Event 

 The term “Insolvency Event” shall have the meaning set forth in the
Collaboration Agreement. 
  

	1.22	JOC 

 The term “JOC” shall mean the joint operating committee described in the Ex-US Commercialization Agreement. 
  

	1.23	Know-How 

 The term “Know-How” shall mean data,
knowledge and information, including related to CGP, manufacturing data, toxicological data, pharmacological data, preclinical data, formulations, specifications, quality control testing data. 

 

	1.24	Party 

 The term “Party” shall mean FMI or Genentech, as the case may be, and
“Parties” shall mean FMI and Genentech collectively. 
  

	1.25	PREP Team 

 The term “PREP Team” shall mean Genentech’s field-based team of professions referred to as the PREP (Program for Reaching and Educating about Pathology) team, or any other Genentech group performing similar functions, as further described in the Tactical
Plan. 
  

	1.26	Regulatory Authority 

 The term “Regulatory Authority” shall have the meaning set forth in the
Collaboration Agreement. 
  

	1.27	Roche Group 

 The term “Roche Group” shall have the meaning set forth in the Collaboration
Agreement. 

  
 - 7 - 

	1.28	Tactical Plan 

 The term “Tactical Plan” shall mean a plan for the [...***...] that
describes the responsibilities of the Parties for implementing the Education Support Program, as further described in Section 2.1.5. 
  

	1.29	Third Party 

 The term “Third Party” shall mean a person or entity other than (a) FMI or
any of its Affiliates or (b) a member of the Roche Group. 
  

	1.30	US 

 The term “US” shall mean the United States of America and its territories and possessions.

  

	1.31	US$ 

 The term “US$” shall mean US dollars. 

 

	1.32	Additional Definitions 

 Each of the following definitions is set forth in the Section of this Agreement
indicated below: 
  

			
	 Definition
	  	 Section

	Bankruptcy Code	  	9.3.2
	Breaching Party	  	9.2.1
	Collaboration Agreement	  	Whereas Clause
	Educational Activities	  	2.1.1
	ESWG	  	1.14
	ESWG Co-Leader	  	2.2.1
	Ex-US Collaboration Agreement	  	Whereas Clause
	FMI Other Materials	  	6.1.3
	FMI Provided Materials	  	6.1.1
	FTE Costs	  	3.1
	Non-Breaching Party	  	9.2.1
	Other Costs	  	3.1
	Payment Currency	  	4.3
	Peremptory Notice Period	  	9.2.1
	Related Agreements	  	Whereas Clause
	Roche	  	Whereas Clause
	Roche Basel	  	Whereas Clause
	Roche US	  	Whereas Clause
	[...***...]	  	3.1
	Training Activities	  	2.1.2
	Training Materials	  	2.1.2

  
 ***Confidential Treatment
Requested*** 
 - 8 - 

	2.	US Education Collaboration 

  

	2.1	Education Support Program 

  

	 	2.1.1	Scope 

 Genentech and FMI shall conduct the Education Support Program pursuant to a mutually agreed Tactical
Plan under the direction of the Education Support Working Group (also referred to as the “ESWG”). The purpose of the Education Support Program is for Genentech to provide education support directed to healthcare professionals regarding
comprehensive genomic profiling (CGP), using next generation sequencing technology or other technologies that may emerge for CGP (“Educational Activities”). 
  

	 	2.1.2	Training Activities and Training Materials 

 FMI shall provide training to Genentech regarding CGP and other
topics, as agreed to by the Parties in the Tactical Plan, subject to the limitations in Section 2.1.7 and other provisions of this Agreement (“Training Activities”). The Training Activities shall take place in the location and on
the schedule in the Tactical Plan. As part of the Training Activities, FMI shall provide to Genentech information and materials related to CGP (“Training Materials”). FMI shall prepare the Training Activities and Training Materials
with content based on competent and reliable scientific and medical principles. The Training Activities and Training Materials must be non-commercial in tone, focus and content and must make a fair and
balanced representation of the positive and negative attributes and uncertainties of CGP. The Training Activities and Training Materials must not incorporate promotional, commercial or marketing messages for FMI or its products including, without
limitation, FoundationOne or FoundationOne Heme. Notwithstanding anything to the contrary, in conducting the Training Activities, FMI may use its proprietary platform and CGP testing panels to provide a specific demonstration of how CGP may be
performed. 
  

	 	2.1.3	Educational Materials 

 FMI shall provide the Training Materials to Genentech in hardcopy form and in electronic
form for use in preparing the Educational Materials. Genentech shall be responsible, in collaboration with FMI, for developing the content and appearance of the Educational Materials, to be used by Genentech as part of the Education Support Program.
In preparing the Educational Materials, Genentech will draw upon relevant information included in the Training Activities, upon the relevant expertise of the PREP Team and other Genentech and Roche experts, and upon external sources of scientific
and medical information that Roche/Genentech determines to be competent and reliable. The Educational Materials will include only scientific and medical information regarding CGP that Genentech determines to be competent and reliable and will make a
fair and balanced presentation of the positive and negative attributes and uncertainties of CGP. Genentech shall provide a copy of the Educational Materials to FMI for review and comment; provided, however, Genentech shall have final decision making
authority regarding the Educational Materials. 

  
 - 9 - 

	 	2.1.4	Additional and Updated Training Activities 

 The Education Support Working Group shall confer regarding the
need, timing and location for (a) additional Training Activities for members who join the PREP Team after the initial Training Activities occur and (b) updated Training Activities for previously trained PREP Team members, based
on the emergence of new technology relevant to CGP. FMI and Genentech shall, respectively, use Commercially Reasonable Efforts to provide and attend any such additional or updated Training Activities. 

 

	 	2.1.5	Tactical Plan 

 The Tactical Plan in effect as of the Effective Date is attached as Appendix 2.1.5.
Genentech shall update the Tactical Plan [...***...], on the schedule determined by the Education Support Working Group (and at times as otherwise agreed by the ESWG, including for additional and updated Training Activities, as described in
Section 2.1.4), for review and approval by the ESWG. The details included in the Tactical Plan will vary to address the objectives of the Parties, but shall include, as applicable, details regarding (a) the Training Activities, including
training materials and timelines; (b) the scope of the Educational Materials and a plan for developing them; (c) the scope and target audiences for the Educational Activities by the PREP Team, using the Educational Materials or
otherwise; (d) a budget of estimated [...***...], and each Party’s portion of particular [...***...] (which portions may vary for particular costs); and (e) information to be shared by the Parties and the timing and means
for sharing such information (e.g., through the ESWG or otherwise). For any Educational Activities in a Tactical Plan conducted by PREP Team members, the Parties agree that any activities that Genentech agrees to perform will be reduced
pro rata for any period of time that a PREP team position is unstaffed and that an unstaffed position will not be deemed filled until a PREP Team member has attended Training Activities and been trained on the Educational Materials.
Information that one Party shares with or provides to the other Party under the Tactical Plan shall be Confidential Information of the sharing or providing Party. 
  

	 	2.1.6	Regulatory and Compliance Matters 

 (a) The Parties intend that (i) the Parties’
activities will be in all respects compliant with Applicable Laws and (ii) Genentech’s Educational Activities under the Tactical Plan will be structured and conducted so as to be educational disease awareness communications disseminated to
healthcare professionals that discuss a particular disease or health condition, in order to encourage awareness of signs of the particular disease or heath condition or otherwise provide information to assist in the diagnosis of the particular
disease or health condition, but do not mention any specific drug or device or make any representation or suggestion concerning a particular drug or device, and do not otherwise constitute product advertising or promotional labeling of a drug or
medical device. 
 (b) Each Party shall be solely responsible for matters of compliance with Applicable Laws with respect to its conduct of
activities under this Agreement and for interactions with Regulatory Authorities and Government Agencies with respect thereto, as follows: FMI shall be responsible for 

  
 ***Confidential Treatment
Requested*** 
 - 10 - 

 
its conduct of the Training Activities; Genentech shall be responsible for its preparation of the Educational Materials and the conduct of the Educational Activities; and both Parties will be
responsible for the establishment of priorities and tactics in the Tactical Plan and for discussions and sharing of information at the Education Support Working Group and otherwise between the Parties under this Agreement. If either Party receives a
communication from a Regulatory Authority or Government Agency that its activities under this Agreement may violate or have violated any Applicable Law or regulation, including any notice of claim, demand, suit, investigation or proceeding that
relates or may reasonably relate to any such activities, such Party shall promptly share that communication with the other Party, and the Parties shall confer on an appropriate response, provided that (i) the Party receiving the communication
shall remain free to take any or no action in response to such communication including, without limitation, terminating this Agreement under Section 9.2.2 and (ii) if both Parties are responsible for any of the activities under this Agreement
(as specified in this Section 2.1.6(b)) potentially relevant to such claim, demand, suit, investigation or proceeding, then the Parties shall discuss in good faith how to respond to it and how to handle it in an efficient manner. 

 

	 	2.1.7	Limitations on Activities 

 The Parties acknowledge and agree to the following: 

(a) This Agreement (individually or together with the Related Agreements) is not intended for the promotion in the US by Genentech of any
Genentech products or any FMI products or services (including, without limitation, FoundationOne or FoundationOne Heme) or for the promotion in the US by FMI of any Genentech products or any FMI products or services (including, without limitation,
FoundationOne or FoundationOne Heme), provided that nothing in the foregoing or elsewhere in this Agreement or the Related Agreements shall limit each Party in promoting its own products or services separate from and outside the scope of this
Agreement and the Related Agreements. 
 (b) Neither Party shall, under this Agreement, provide to or discuss with the other Party any of
such Party’s promotional strategies, plans or tactics for its products or services. Notwithstanding the foregoing, the Parties may discuss any activities of the PREP Team. 

(c) Genentech and its agents shall not recommend or mention FMI products or services (including, without limitation, FoundationOne or
FoundationOne Heme) in the course of Educational Activities and will not refer any audiences to FMI or its products or services. The Educational Materials and educational messaging that Genentech uses in the Educational Activities shall not include
any branding or references to either Party’s products or services. Notwithstanding the foregoing, company level branding (e.g., a Party’s logo) may be included as required by Applicable Law or accepted industry codes or practices, or
for purposes of corporate transparency. Without limiting the foregoing, any such branding shall be subject to the agreement of the Parties through the Education Support Working Group. Without limiting the generality of the foregoing, any promotion,
recommendation, or referral by either Party of or to the other or the other’s products or services in the US may only occur pursuant to a separate agreement or an amendment to this Agreement. 

(d) The Parties acknowledge that, currently, reports for patients generated through FoundationOne include mention of Genentech products as
being approved to treat tumors with 

  
 - 11 - 

 
particular types of mutations identified in such patients’ tumors in the FoundationOne test and the same may be done in the future for the FoundationOne Heme test on the same principles. The
Parties do not intend, through this Agreement or any Related Agreement, to compensate, encourage or incentivize FMI to make, change or prioritize such mentions of Genentech products in FoundationOne or as part of any other FMI product or services.
FMI covenants that it will not, by reason of its relationships with Genentech or Roche under this Agreement or the Related Agreements, change its practices in how it promotes, advertises, offers or provides FoundationOne, FoundationOne Heme or any
other product or service that it offers (including, without limitation, by changing how Genentech products are presented or mentioned in any such product or service report or how any potential association between a reported mutation and a Genentech
product is presented or mentioned). 
  

	 	2.1.8	Diligence and Activities 

 The Parties shall use Commercially Reasonable Efforts to perform their respective
activities under the Tactical Plan and as otherwise contemplated by this Agreement. The Parties shall perform all activities under this Agreement (a) in a professional manner; (b) in conformance with the level or care and skill ordinarily
exercised by other professional institutions in similar circumstances; and (c) in compliance with Applicable Law. 
  

	 	2.1.9	Third Party Contractors and Affiliates 

 Neither Party shall have the right to subcontract to Third Parties the
work for which it is responsible under the Tactical Plan or otherwise under this Agreement, except for activities customarily subcontracted by such Party, including the preparation or production of Training Materials or Educational Materials
and planning or coordination of Training Activities or Educational Activities. For clarity, none of the following activities may be subcontracted without the other Party’s prior written consent to subcontract (which may be provided by email to
the subcontracting Party’s ESWG Co-Leader): (a) for Genentech, (i) membership on, and participation in discussions and decision making of, the ESWG; (ii) PREP Team attendance at Training
Activities; (iii) oversight of preparation of, and final review and approval of, Educational Materials; (iv) educational calls including CGP education that are made by PREP Team members on healthcare professionals, laboratories and others
included within the target audience, as described in the Tactical Plan; (v) oversight of preparation of, and final review and approval of, materials for unbranded speaker programs including CGP education, as described in the Tactical Plan and
included in Educational Activities; (vi) on-site presence for and oversight of unbranded speaker programs including CGP education, as described in the Tactical Plan and included in Educational Activities; (vii) information-sharing as
required under the Tactical Plan; and (viii) discussions with FMI on communications from Government Agencies under Section 2.1.6(b) and (b) for FMI, (i) membership on, and participation in discussions and decision making of, the ESWG;
(ii) oversight of preparation of, and final review and approval of, Training Materials; (iii) conduct of Training Activities; (iv) information-sharing as required under the Tactical Plan; and (v) discussions with Genentech on
communications from Government Agencies under Section 2.1.6(b). Each Party shall have the right to perform its obligations under this Agreement through its Affiliates. Each Party shall remain fully responsible for and liable to the other Party
for the performance of activities under this Agreement by such Third Parties or Affiliates. 

  
 - 12 - 

	2.2	Governance 

  

	 	2.2.1	Establishment of the ESWG 

 The Parties shall establish the Education Support Working Group within
[...***...] after the Effective Date to operationalize the Education Support Program. The ESWG shall be composed of at least two (2), but no more than three (3) representatives designated by each Party (and the Parties need not have the
same number of representatives). The representatives shall be appropriate (in terms of their seniority, availability, function in their respective organizations, training and experience) for the activities for which the ESWG is responsible. Each
Party shall designate one of its representatives as its primary contact for ESWG matters (such Party’s “ESWG Co-Leader”). A Party may replace any or all of its representatives (and
designated ESWG Co-Leader) at any time by informing the other Party’s ESWG Co-Leader in advance, in writing (which may be by email). 

 

	 	2.2.2	Responsibilities of the ESWG 

 The Education Support Working Group shall: 

(a) review and approve [...***...] Tactical Plans and revisions to the Tactical Plans, each of which [...***...] plan and revision
Genentech shall prepare in accordance with Section 2.1.5; 
 (b) serve as a forum for coordinating the Parties’ efforts to carry
out the Tactical Plan; 
 (c) monitor the progress of activities under the Tactical Plan and discuss any obstacles or delays with regard to
achieving the timelines set forth therein; 
 (d) within [...***...] following the end of each [...***...] in which
[...***...] are incurred by a Party, coordinate, and/or be the primary conduit for, providing to the other Party a good faith estimate of such incurred [...***...] (which may differ from the actual invoice) in writing (which may be by
email); 
 (e) provide reports and other information to the JOC regarding activities under the Tactical Plan, as requested by the JOC; 

(f) coordinate, and/or be the primary conduit for, the transfer of information between the Parties, as required by the Tactical Plan; and 

(g) perform other responsibilities as may be assigned to the ESWG in or pursuant to this Agreement or as may be otherwise agreed by the
Parties in writing. 
  

	 	2.2.3	Decision Making Authority of the ESWG 

 With respect to the responsibilities of the Education Support Working
Group, each Party shall have one (1) collective vote in all decisions, and the Parties shall attempt to make decisions by reaching agreement. Except with respect to matters for which one Party expressly has final decision making authority
(e.g., Section 2.1.2 with respect to Educational Materials), if the ESWG cannot reach agreement within [...***...]. Genentech acknowledges that it will be represented by Roche on the JOC. The ESWG has no authority to amend, or to
waive compliance with, any provisions of this Agreement. 

  
 ***Confidential Treatment
Requested*** 
 - 13 - 

	 	2.2.4	ESWG Co-Leaders 

 Genentech’s ESWG Co-Leader (or its designee)
shall be responsible for the following: (a) scheduling Education Support Working Group meetings and setting meeting agendas; (b) calling emergency ESWG meetings; and (c) any additional responsibilities specified in the Agreement;
provided, however, FMI’s Co-Leader has the right to schedule meetings, raise matters for discussion and put matters to a vote. 
  

	 	2.2.5	Meetings; Attendees 

 Once established, the Education Support Working Group shall meet at least once each
[...***...] (unless otherwise agreed by the Parties), and shall meet at such other times as deemed appropriate by the ESWG. The ESWG may meet in person or via teleconference, video conference or the like, provided that at least
[...***...] shall be held in person, unless otherwise agreed by the Parties. Each Party shall bear the expense of its respective representatives’ participation in ESWG meetings. If a Party’s representative (including its ESWG Co-Leader) is unable to attend a given meeting, such Party may designate a knowledgeable alternate to attend such meeting and perform the functions of such representative. Each Party may, subject to providing prior
notice to the other Party’s ESWG Co-Leader (which may be by email), invite a reasonable number of non-voting employees, consultants or advisors to attend ESWG
meetings, provided that such invitees are bound by confidentiality and non-use obligations reasonably similar to the Parties’ obligations under this Agreement. In addition to formal meetings, the ESWG
representatives shall communicate as necessary to ensure the appropriate direction of the Education Support Program. 
  

	 	2.2.6	Minutes; Other Documentation of Decisions 

 Promptly after the Education Support Working Group is established,
it shall hold an organizational meeting to define the ESWG’s operating procedures, including for establishing agendas and preparing and approving minutes. Genentech shall be responsible for keeping minutes of ESWG meetings that record in
writing all decisions made, action items assigned or completed and other appropriate matters. Meeting minutes shall be sent to both Parties promptly after a meeting for review, comment and approval by each Party. A decision that may be made at a
ESWG meeting may also be made, without a meeting, if such decision is agreed to in writing (including by email) by each Party’s ESWG Co-Leader (or its designee), provided that each Party’s writing
clearly indicates that such decision is a formal decision by such Party’s ESWG Co-Leader. Any modifications to the Tactical Plan approved at a ESWG meeting (in accordance with the decision making
authority provisions of Section 2.2.3) shall constitute an amendment to such Tactical Plan upon approval by both Parties of the meeting minutes related thereto. 
  

	 	2.2.7	Term of ESWG Operations 

 The Education Support Working Group shall exist during the Agreement Term. 

  
 ***Confidential Treatment
Requested*** 
 - 14 - 

	3.	Costs 

  

	3.1	[...***...] 

 In accordance with the Tactical Plan, the Parties shall share [...***...]. FMI shall
reimburse Genentech for [...***...]. 
  

	3.2	Other Costs 

 Unless otherwise expressly agreed in the Tactical Plan, each Party shall bear the costs it
incurs in connection with the Training Activities and/or Educational Activities, including transportation, meals, lodging and the time necessary for representatives to prepare for and attend the Training Activities. Genentech shall be solely
responsible for the costs of producing the Educational Materials. 
  

	3.3	Disclosure of Payments 

 Each Party acknowledges that the other Party may be obligated to disclose
financial arrangements made with third parties to carry out certain activities under the Tactical Plan, including all fees, payments and transfers of value, as may be advisable or required under Applicable Law, including the US Sunshine Act.

  

	4.	Payments 

  

	4.1	Timing of Payments 

 FMI shall pay its portion of the [...***...] in arrears. Each
[...***...], Genentech shall invoice FMI for its portion of actual [...***...] incurred in the previous [...***...]. Invoices shall be payable within [...***...] after receipt by FMI of an invoice from Genentech. 

 

	4.2	Late Payments 

 Any payment under this Agreement that is not paid on or before the date such payment is
due shall bear interest, to the extent permitted by Applicable Law, at [...***...] above the average one-month Euro Interbank Offered Rate (EURIBOR), as reported by Reuters from time to time, calculated on the number of days such payment is
overdue. 
  

	4.3	Method of Payments 

 All amounts payable hereunder shall be paid in US dollars (the “Payment
Currency”) to account(s) designated by Genentech. 

  
 ***Confidential Treatment
Requested*** 
 - 15 - 

	5.	Co-Promote Option 

 If FMI seeks to promote a CDx (as defined in the Collaboration Agreement) for a
Genentech therapeutic in the US, then FMI shall first notify Genentech in writing and offer to Genentech [...***...]. Genentech shall have [...***...] from the receipt of such notice from FMI to provide FMI with [...***...]. If at
the end of such [...***...] period Genentech has not provided FMI with written notice [...***...], then FMI shall have no further obligation with respect to [...***...]. If Genentech properly [...***...], then the Parties
shall [...***...]. Notwithstanding the foregoing, FMI shall have the right to promote such product alone, at any time during such [...***...], and following such [...***...] period, in combination with one or more Third Parties. In
addition to the provisions surviving under Section 9.4, this Section shall survive the expiration or termination of this Agreement for so long as the CDx Development Program (as defined in the Collaboration Agreement) remains in effect, except
in the case of termination by FMI for Genentech’s material breach. 
  

	6.	Intellectual Property 

  

	6.1	Ownership and Use 

  

	 	6.1.1	FMI Provided Materials 

 In connection with the Training Activities (or otherwise under this Agreement), FMI may
provide to Genentech certain Know-How and other materials (“FMI Provided Materials”). FMI shall only provide FMI Provided Materials to Genentech that FMI Controls and otherwise has all
necessary rights to (a) provide such FMI Provided Materials to Genentech and (b) grant the license under Section 6.1.2 to Genentech and its Affiliates. FMI possesses (or may possess) proprietary rights (e.g., copyrights) in
certain of the FMI Provided Materials and, as between the Parties (subject to such license to Genentech), FMI shall solely own all right, title and interest in and to the FMI Provided Materials. For the avoidance of doubt, certain FMI
Provided Materials may be subject to Third Party proprietary rights (e.g., copyrights) and Genentech’s use thereof is subject to such rights. At the time FMI provides to Genentech any FMI Provided Materials that include content subject to
the proprietary rights of a Third Party, FMI shall identify in writing such Third Party content and the identity of such Third Party. 
  

	 	6.1.2	License Grant to Genentech; Educational Materials 

 FMI hereby grants to Genentech and its Affiliates a non-exclusive, perpetual, fully paid-up, irrevocable, non-sublicensable, worldwide license to incorporate FMI Provided Materials in the Educational Materials and similar
materials and to otherwise use the FMI Provided Materials in the Educational Activities and similar activities, including the right to create, reproduce and distribute the Educational Materials and similar materials and to authorize others to
do so on its behalf, in each case, subject to copyrights or similar rights of Third Parties; provided however, such license shall not include any right or license under FMI’s intellectual property rights to FMI’s corporate or product trade
names or trademarks. As between the Parties, Genentech shall solely own all right, title and interest in and to the Educational Materials and similar materials (excluding FMI Provided Materials and FMI Other Materials), and Genentech may, and may
have any authorized designee acting on behalf of Genentech, use the Educational Materials and similar materials for Genentech’s own purposes, including outside the scope of this Agreement. 

  
 ***Confidential Treatment
Requested*** 
 - 16 - 

	 	6.1.3	License Grant to FMI; FMI Other Materials 

 Genentech hereby grants to FMI and its Affiliates a non-exclusive, perpetual, fully paid-up, irrevocable, non-sublicensable, worldwide license to incorporate Genentech originated content
included in the Educational Materials in materials to be used by FMI for its own purposes (“FMI Other Materials”), including the right to create, reproduce and distribute FMI Other Materials including such content and to authorize
others to do so on its behalf, in each case, subject to copyrights or similar rights of Third Parties; provided, however such license shall not include any right or license under Genentech’s intellectual property rights to Genentech’s
corporate or product trade names or trademarks. FMI shall use trade dress (fonts, color scheme, design attributes) in connection with the FMI Other Materials sufficiently different from the trade dress of the Educational Materials so as not to
create any confusion, or mislead a reasonable person, as to whether Genentech is the owner or source of the FMI Other Materials. Prior to the initial instance of reproduction or distribution of FMI Other Materials to Third Parties, FMI shall provide
copies of such FMI Other Materials to Genentech. For the avoidance of doubt, certain Educational Materials may be subject to Third Party proprietary rights (e.g., copyrights) and FMI’s use thereof is subject to such rights. At the time
Genentech provides to FMI any Educational Materials that include content subject to the proprietary rights of a Third Party (other than such content that was provided by FMI to Genentech), Genentech shall identify in writing such Third Party content
and the identity of such Third Party. 
  

	6.2	No Implied Licenses 

 Except as specifically set forth herein, this Agreement shall not be construed as
(a) giving a Party any license, right, title, interest in or ownership to the Confidential Information or other proprietary information or materials of the other Party; (b) granting to a Party any license or right under any intellectual
property rights of the other Party; or (c) representing any commitment by either Party to enter into any additional agreement, by implication or otherwise. 
  

	7.	Representations and Warranties 

  

	7.1	Mutual Representations and Warranties 

 FMI and Genentech each represent and warrant that it: 

(a) has all requisite power and authority to enter into and perform its obligations under this Agreement; 

(b) has no outstanding agreement or obligation that is in conflict with any of the provisions of this Agreement or that would preclude its
personnel from complying with the provisions hereof; and 
 (c) will perform all activities under this Agreement (i) in a professional
manner, (ii) in conformance with the level or care and skill ordinarily exercised by other professional institutions in similar circumstances, and (iii) in compliance with Applicable Law. 

  
 - 17 - 

	7.2	No Other Representations 

 EXCEPT AS OTHERWISE PROVIDED IN THIS AGREEMENT AND THE RELATED AGREEMENTS
BEING ENTERED INTO BY THE PARTIES AT THIS TIME, THE FOREGOING REPRESENTATIONS AND WARRANTIES ARE IN LIEU OF ALL OTHER REPRESENTATIONS AND WARRANTIES, EXPRESS OR IMPLIED, INCLUDING WITHOUT LIMITATION, WARRANTIES OF MERCHANTABILITY OR FITNESS FOR A
PARTICULAR PURPOSE OF PRODUCTS. 
  

	8.	Liability 

 IN NO EVENT SHALL EITHER FMI OR GENENTECH BE LIABLE FOR SPECIAL, INDIRECT, INCIDENTAL OR
CONSEQUENTIAL DAMAGES ARISING OUT OF THIS AGREEMENT BASED ON CONTRACT, TORT OR ANY OTHER LEGAL THEORY. 
  

	9.	Term and Termination 

  

	9.1	Commencement and Term 

 This Agreement shall commence upon the Effective Date, and unless terminated
sooner as provided in Article 9, continue for the Agreement Term. 
  

	9.2	Termination 

  

	 	9.2.1	Termination for Breach 

 A Party (“Non-Breaching
Party”) shall have the right to terminate this Agreement in its entirety in the event the other Party (“Breaching Party”) is in breach of any of its material obligations under this Agreement. The Non-Breaching Party shall provide written notice to the Breaching Party, which notice shall identify the breach. The Breaching Party shall have a period of [...***...] after such written notice is provided
(“Peremptory Notice Period”) to cure such breach. If the Breaching Party has a bona fide dispute as to whether such breach occurred or has been cured, it will so notify the
Non-Breaching Party, and the expiration of the Peremptory Notice Period shall be tolled until such dispute is resolved pursuant to Section 11.2. Upon a determination of breach or failure to cure, the
Breaching Party may have the remainder of the Peremptory Notice Period to cure such breach. If such breach is not cured within the Peremptory Notice Period, then absent withdrawal of the Non-Breaching
Party’s request for termination, this Agreement shall terminate effective as of the expiration of the Peremptory Notice Period. 
  

	 	9.2.2	Termination for Regulatory, Compliance and Other Matters 

 A Party shall have the right to terminate this
Agreement on [...***...] notice and to immediately suspend any affected activities under the Agreement, if (a) it receives a communication from a Government Agency to the effect that one or more activities by either or both Parties under
the 

  
 ***Confidential Treatment
Requested*** 
 - 18 - 

 
Agreement violates Applicable Law including, without limitation, any Healthcare Law, and regulations promulgated under the foregoing laws; (b) a Government Agency promulgates a regulation
during the Agreement Term that is or would be violated by one or more activities by either or both Parties under the Agreement; (c) a Government Agency issues an opinion, guidance or interpretation during the Agreement Term that reasonably
indicates that it is the position of such Government Agency that activities of the nature of one or more activities by either or both Parties under the Agreement violates or would violate Applicable Law including, without limitation any Healthcare
Law, and regulations promulgated under any such laws; or (d) such Party has a right to terminate the Agreement under Section 2.2.3. 
  

	 	9.2.3	Termination for Insolvency 

 A Party shall have the right to terminate this Agreement, if the other Party incurs
an Insolvency Event; provided, however, in the case of any involuntary bankruptcy proceeding, such right to terminate shall only become effective if the Party that incurs the Insolvency Event consents to the involuntary bankruptcy or such proceeding
is not dismissed within [...***...] after the filing thereof. 
  

	 	9.2.4	Termination Without a Cause 

 Each Party shall have the right to terminate this Agreement in its entirety, in
its sole discretion, during the first Calendar Year of the Agreement upon six (6) months’ prior written notice to the other Party and thereafter upon three (3) months’ prior written notice to the other Party. 

 

	9.3	Consequences of Termination 

  

	 	9.3.1	Accrued Rights and Obligations 

 Except as otherwise expressly provided in this Agreement, termination of this
Agreement shall not affect the rights and obligations of the Parties that accrued prior to the effective date of such termination, including any obligation that FMI has to make payments to Genentech that are due and payable prior to the effective
date of termination. Any right that a Party has to terminate this Agreement, and any rights that such Party has under Article 9, shall be in addition to and not in lieu of all other rights or remedies that such Party may have at law or in
equity or otherwise, including rights under the Bankruptcy Code. 
  

	 	9.3.2	Bankruptcy 

 All licenses (and to the extent applicable rights) granted under or pursuant to this Agreement by
FMI to Genentech are, and shall otherwise be deemed to be, for purposes of Section 365(n) of Title 11, US Code (“Bankruptcy Code”) licenses of rights to “intellectual property” as defined under
Section 101 of the Bankruptcy Code. 
  

	9.4	Survival 

 Article 6 (Intellectual Property), Article 7 (Representations and Warranties),
Article 8 (Liability), Article 9 (Term and Termination), Article 10 (Matters Governed by the Collaboration Agreement), and Article 11 (Miscellaneous) (to the extent applicable) shall survive any expiration or termination of this
Agreement for any reason. 

  
 ***Confidential Treatment
Requested*** 
 - 19 - 

	10.	Matters Governed by the Collaboration Agreement 

  

	10.1	Auditing 

 Except as otherwise specified herein, the auditing provisions of the Collaboration Agreement
shall apply any payments made by one Party to the other Party under this Agreement (e.g., with respect to payments by FMI to Genentech for FTE Costs) mutatis mutandis. 

 

	10.2	Indemnification 

 Except as otherwise specified herein, the indemnification provisions of the
Collaboration Agreement shall apply to this Agreement mutatis mutandis. 
  

	10.3	Confidentiality 

 Except as otherwise specified herein, the confidentiality provisions of the
Collaboration Agreement shall apply to any Confidential Information obtained by a Party or its Affiliates under this Agreement mutatis mutandis. 
  

	10.4	Assignment 

 Except as otherwise specified herein, the assignment provisions of the Collaboration
Agreement shall apply to this Agreement mutatis mutandis. 
  

	10.5	Debarment and Exclusion 

 Except as otherwise specified herein, the Parties’ representations,
warranties and covenants with respect to debarment and exclusion in the Collaboration Agreement shall apply to this Agreement mutatis mutandis. 
  

	11.	Miscellaneous 

  

	11.1	Governing Law 

 This Agreement shall be governed by and construed in accordance with the laws of New
York, US, without reference to its conflict of laws principles, and shall not be governed by the United Nations Convention of International Contracts on the Sale of Goods (the Vienna Convention). 

 

	11.2	Disputes 

 Unless otherwise set forth in this Agreement (e.g., Section 2.2.3), in the event of
any dispute in connection with this Agreement, such dispute shall be referred to the respective executive officers of the Parties designated below or their designees, for good faith negotiations attempting to resolve the dispute. The designated
executive officers are as follows: 
 For FMI: CEO 

For Genentech: Head of Roche Partnering 

  
 - 20 - 

 Should the Parties fail to agree within the time period set forth in the Collaboration Agreement for dispute
resolution by the Parties, except as otherwise specified herein, the arbitration provisions of the Collaboration Agreement shall apply to disputes arising under this Agreement mutatis mutandis. 

 

	11.3	Independent Contractor 

 No employee or representative of either Party shall have any authority to bind
or obligate the other Party to this Agreement for any sum or in any manner whatsoever or to create or impose any contractual or other liability on the other Party without said Party’s prior written approval. For all purposes, and
notwithstanding any other provision of this Agreement to the contrary, FMI legal relationship to Genentech under this Agreement shall be that of independent contractor. 
  

	11.4	Unenforceable Provisions and Severability 

 If any of the provisions of this Agreement are held to be
void or unenforceable, then such void or unenforceable provisions shall be replaced by valid and enforceable provisions that will achieve as far as possible the economic business intentions of the Parties. However the remainder of this Agreement
will remain in full force and effect, provided that the material interests of the Parties are not affected, i.e., the Parties would presumably have concluded this Agreement without the unenforceable provisions. 

 

	11.5	Waiver 

 The failure by either Party to require strict performance and/or observance of any obligation,
term, provision or condition under this Agreement will neither constitute a waiver thereof nor affect in any way the right of the respective Party to require such performance and/or observance. The waiver by either Party of a breach of any
obligation, term, provision or condition hereunder shall not constitute a waiver of any subsequent breach thereof or of any other obligation, term, provision or condition. 
  

	11.6	Appendices 

 All Appendices to this Agreement shall form an integral part to this Agreement. 

 

	11.7	Entire Understanding 

 This Agreement contains the entire understanding between the Parties hereto with
respect to the within subject matter and supersedes any and all prior agreements, understandings and arrangements, whether written or oral. 
  

	11.8	Amendments 

 No amendments of the terms and conditions of this Agreement shall be binding upon either
Party hereto unless in writing and signed by both Parties. 
  

	11.9	Invoices 

 All invoices that are required or permitted hereunder shall be in writing and sent by
Genentech to FMI by email at the following address or other address as FMI may later provide: 
 Foundation Medicine, Inc. 

ap@foundationmedicine.com 

  
 - 21 - 

	11.10	Notice 

 All notices that are required or permitted hereunder shall be in writing and sufficient if
delivered personally, sent by facsimile (and promptly confirmed by personal delivery, registered or certified mail or overnight courier), sent by nationally recognized overnight courier or sent by registered or certified mail, postage prepaid,
return receipt requested, addressed as follows: 
  

			
	if to FMI, to:		 Foundation Medicine, Inc.
 150 Second Street

Cambridge, Massachusetts 02141
 Attn: Legal Department

Facsimile No.: +1 617-418-2201

		
	if to Genentech, to:		 Genentech, Inc.
 1 DNA Way

Attn: Corporate Secretary
 Facsimile No.: +1
650-467-9146

		
	and:		 Genentech, Inc.
 1 DNA Way

Attn: Global Head, Alliance and Asset Management
 Facsimile No.:
+1 650-467-3294

 or to such other address as the Party to whom notice is to be given may have furnished to the other Party in writing in
accordance herewith. 
 [Signature Page Follows] 

  
 - 22 - 

 IN WITNESS WHEREOF, the Parties have entered into this Agreement as of the Effective Date. 

 

			
	Foundation Medicine, Inc.
	
	 /s/ Steven J. Kafka

		
	Name:		Steven J. Kafka
		
	Title:		Chief Operating Officer

  

			
	Genentech, Inc.
	
	 /s/ Ian T. Clark

		
	Name:		Ian T. Clark
		
	Title:		Chief Executive Officer

  
 - 23 - 

 Appendix 2.1.5 

Tactical Plan 
 US
Education Collaboration Agreement 
 2015 Tactical Plan 

Capitalized terms used in this Tactical Plan shall have the meaning given them in the US Education Collaboration Agreement unless otherwise defined
herein. 
 Term: Effective Date to December 31, 2015 
 A.
Training Activities 
 [...***...]. 
 B.
Development of Educational Materials 
 [...***...]. 

C. PREP Educational Activities 
 [...***...]. 

D. Educational Speaker Programs 
 [...***...]. 

E. Information Sharing 
 [...***...]. 

F. Costs and Compensation 
 [...***...]. 

G. [...***...] Tactical Plan 
 The Parties,
through the ESWG, will consider whether to incorporate a CGP education effectiveness metric to be tracked and assessed for the [...***...] tactical plans and/or subsequent tactical plans as they develop more insight and experience with this
collaboration. 

  
 ***Confidential Treatment
Requested*** 
 A-1

Source: [{"source": "alea-institute/alea-institute/kl3m-data-edgar-agreements/train-00249-of-00352.parquet"}, [{"source": "alea-institute/alea-institute/kl3m-data-edgar-agreements/train-00249-of-00352.parquet"}]]